The Pediatric Artificial Pancreas (PEDAP) trial: A 1 
Randomized Controlled Comparison of the Control - 2 
IQ technology Versus Standard of Care in Young 3 
Children in Type 1 Diabetes  4 
Study Sponsor  5 
Marc D. Breton , Ph.D. 6 
University of Virginia  7 
Center for Diabetes Technology  8 
 Protocol Chair  9 
R. Paul Wadwa, MD  10 
Barbara Davis Center  11 
University of Colorado  12 
Participating Institutions  13 
University of Virginia, Charlottesville, Virginia  14 
Barbara Davis Center, University of Colorado, Colorado  15 
Stanford University, California  16 
 17 
Coordinating Center  18 
Jaeb Center for Health Research  19 
 20 
 21 
 22 
  Version Number: v11 .0  / NCT# 04796779 23 
DECEMBER 3, 2021 24 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 2 OF 84 
 KEY ROLES  25 
 
Sponsor  Chair / IDE Chair   
Name, degree Marc D. Breton , Ph.D. 
Institution Name  University of Virginia, Center for Diabetes Technology  
  
Protocol Chair/Director   
Name, degree R. Paul Wadwa, MD  
Institution Name  Barbara Davis Center, University of Colorado  
 
JCHR Coordinating Center Director  
Name, degree John Lum, MS  
Institution Name  Jaeb Center for Health Research  
 
Medical Monitor   
Name, degree Roy Beck, M.D., Ph.D.  
Institution Name  Jaeb Center for Health Research  
 26 
  27 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 3 OF 84 
 PROTOCOL VERSION HISTORY  28 
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.0 R. Paul Wadwa  
John Lum  
Roy Beck  R. Paul Wadwa  23 Nov 2020  Original protocol   
2.0 John Lum  R. Paul Wadwa  21 Dec 2020  Pre-clinical revisions to accommodate requests 
for changes by IRB and FDA reviewers  
3.0 John Lum  R. Paul Wadwa  13 Jan 2021  Pre-clinical revisions to accommodate request by 
IRB reviewers for changes to framing of 
extension phase participation  
4.0 John Lum  R. Paul Wadwa  29 Jan 2021  Pre-clinical revisions to visit window details  in 
Chapter s 5 and 6 to ensure that window 
definitions are consistent between RCT and 
Extension period and that associated body text agrees with visit window table text.  Initial 
version used for study.  
5.0 Shannon Hiser, John 
Lum  R. Paul Wadwa  7 May 2021  Addition of inclusion criterion requiring U.S. 
residency; typo correction in 9.2.4  
6.0 John Lum  R. Paul Wadwa  16 Jun 2021  Addition of SUS Questionnaire, addition of the 
use of the new version of Control -IQ for the 
extension phase of the study, updated statistical 
analyses for the extension phase of the study.  
7.0 John Lum  R. Paul Wadwa  15 Jul 2021  Per FDA request, inclusion of all study 
participants in the 13 week + 3 day call, 14- week 
call, and 15 -week visit  
8.0 John Lum  R. Paul Wadwa  10 Sep 2021  Addition of ancillary study during Extension 
Phase to obtain system performance data during meal/exercise challenges ; associated  revisions to 
Stats chapter , plus minor unrelated Stats edits.  
9.0 John Lum  R. Paul Wadwa  04 Oct 2021  Revisions to exercise and meal bolus challenges 
to address FDA requests during IDE review  
10.0 John Lum  R. Paul Wadwa  26 Oct 2021  Revisions to exercise and meal bolus challenges 
to address IRB requests during IRB review  
11.0 John Lum  R. Paul Wadwa  03 Dec 2021  Introduction  of Extended Use period  
 29 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 4 OF 84 
 TABLE OF CONTENTS  30 
CHAPTER 1: BACKGROUND INFORMATION  ............................................................................................. 22 31 
 Introduction .......................................................................................................................... 22  32 
 Rationale  .............................................................................................................................. 22  33 
 Potential Risks and Benefits of the Investigational Device ................................................. 23  34 
1.3.1 K
nown Potential Risks ................................................................................................... 23  35 
1.3.1.1 Potential Risks and Benefits of the CLC System .................................................. 23  36 
1.3.1.2 Risk of Hypoglycemia ........................................................................................... 23  37 
1.3.1.3 Risk of Hyperglycemia .......................................................................................... 23  38 
1.3.1.4 Fingerstick Risks .................................................................................................... 23  39 
1.3.1.5 Subcutaneous Catheter Risks (CGM) .................................................................... 23  40 
1.3.1.6 Risk of Device Reuse ............................................................................................. 24  41 
1.3.1.7 Questionnaires and Focus Groups ......................................................................... 24  42 
1.3.1.8 Other Risks ............................................................................................................ 24  43 
1.3.2 Known Potential Benefits .............................................................................................. 25  44 
1.3.3 Risk Assessment ............................................................................................................ 25  45 
 General Considerations  ........................................................................................................ 25  46 
CHAPTE R 2: STUDY ENROLLMENT AND SCREENING  .............................................................................. 27 47 
 Participant Recruitment and Enrollment .............................................................................. 27  48 
2.1.1 I
nformed Consent and Authorization Procedures .......................................................... 27  49 
 Participant Inclusion Criteria  ............................................................................................... 27  50 
 Participant Exclusion Criteria  .............................................................................................. 28  51 
 Eligibility Assessment and Baseline Data Collection .......................................................... 29  52 
 Historical Information .......................................................................................................... 29  53 
 Screening Testing and Procedures ....................................................................................... 29  54 
 Screen Failures  ..................................................................................................................... 30  55 
CHAPTER 3: CGM  RUN-IN PHASE ............................................................................................................ 31 56 
 CGM Run -in Phase Overview  ............................................................................................. 31  57 
 Initiation of CGM  ................................................................................................................ 31  58 
3.2.1 C
GM Training ................................................................................................................ 31  59 
 Blood Glucose and Ketone Testing ..................................................................................... 32  60 
 Assessment of Successful Completion of the Run-in Phase................................................ 32  61 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 5 OF 84 
 
 Optimization of Insulin Therapy.......................................................................................... 33  62 
CHAPTER 4: RANDOMIZATION VISIT ....................................................................................................... 34 63 
 Visit Timing  ......................................................................................................................... 34  64 
4.1.1 R
andomization ............................................................................................................... 34  65 
4.1.2 Baseline HbA1c Determination ..................................................................................... 34  66 
CHAPTER 5: MAIN STUDY PROCEDURES  ................................................................................................. 35 67 
 Visit and Contact Schedule .................................................................................................. 35  68 
 CGM Initiation and Training ............................................................................................... 35  69 
 Procedures for the CLC Group ............................................................................................ 35  70 
5.3.1 S
tudy Pump Training ..................................................................................................... 35  71 
5.3.2 Initiation of Pump by MDI Participants......................................................................... 36  72 
5.3.3 System Use Guidelines .................................................................................................. 37  73 
5.3.4 Home Use of the Study System ..................................................................................... 37  74 
5.3.5 Study Device Download ................................................................................................ 38  75 
5.3.6 3-Day Phone Contact ..................................................................................................... 38  76 
5.3.7 1- Week Phone Contact  .................................................................................................. 38  77 
5.3.8 2- Week Visit  .................................................................................................................. 38  78 
 Procedures  for the SC Group ............................................................................................... 39  79 
5.4.1 S
tudy Device Data Download ........................................................................................ 39  80 
5.4.2 1- Week Phone Contact  .................................................................................................. 39  81 
5.4.3 2- Week Visit  .................................................................................................................. 39  82 
 Follow-up Visits and Phone Contacts for Both Groups ...................................................... 40  83 
5.5.1 V
isits .............................................................................................................................. 40  84 
5.5.2 Phone Contacts............................................................................................................... 40  85 
5.5.3 Optimization of Insulin Therapy .................................................................................... 40  86 
5.5.4 13- Week Visit  ................................................................................................................ 41  87 
 Early Termination Visit (If Applicable)  .............................................................................. 41  88 
 Unscheduled Visits .............................................................................................................. 41  89 
CHAPTER 6: EXTENSION PHASE PROCEDURES  ....................................................................................... 42 90 
 Visit and Contact Schedule .................................................................................................. 42  91 
 Study Pump Initiation  .......................................................................................................... 42  92 
 Visits, Videoconferences, and Phone Calls for All Participants.......................................... 43  93 
6.3.1 13
-Week + 3 -Day Phone Contact .................................................................................. 43  94 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 6 OF 84 
 6.3.2 14-Week Phone Contact ................................................................................................ 43  95 
6.3.3 15- Week Visit  ................................................................................................................ 43  96 
6.3.4 19- Week Visit  ................................................................................................................ 43  97 
6.3.5 23- Week Phone Call ...................................................................................................... 43  98 
6.3.6 26- Week Visit  ................................................................................................................ 43  99 
6.3.7 Optimization of Insulin Therapy .................................................................................... 43  100 
 Unscheduled Visits .............................................................................................................. 43  101 
 Participant Access to Study Device at Study Closure ......................................................... 44  102 
CHAPTER 7: EXTENDED USE PERIOD PROCEDURES  ............................................................................... 45 103 
 Visit and Contact Schedule .................................................................................................. 45  104 
 Visits, Videoconferences, and Phone Calls for Participants Re-Initiating Study Pump Use 105 
A
fter a Gap in Use ..................................................................................................................... 45  106 
7.2.1 S
tudy Pump Retraining Visit ......................................................................................... 45  107 
7.2.2 3-Day Phone Contact ..................................................................................................... 46  108 
7.2.3 1- Week Phone Contact  .................................................................................................. 46  109 
 Visits, Videoconferences, and Phone Calls for All Participants.......................................... 46  110 
7.3.1 13
-Week Visit and Subsequent Visits Every 13 Weeks ................................................ 46  111 
7.3.2 Fi nal Visit....................................................................................................................... 46  112 
7.3.3 Optimization of Insulin Therapy .................................................................................... 46  113 
 Unscheduled Visits .............................................................................................................. 47  114 
 Partic ipant Access to Study Device at Study Closure ......................................................... 47  115 
CHAPTER 8: STUDY DEVICES  .................................................................................................................... 48 116 
 Description of the Investigational Device ........................................................................... 48  117 
8.1.1 I
nsulin Pump .................................................................................................................. 48  118 
8.1.2 Continuous Glucose Monitoring .................................................................................... 48  119 
8.1.3 Blood Glucose Meter and Strips .................................................................................... 48  120 
8.1.4 Ketone Meter and Strips ................................................................................................ 48  121 
8.1.5 Study Device Accountability Procedures ...................................................................... 48  122 
8.1.6 Blood Ketone Testing .................................................................................................... 48  123 
 Safety Measures  ................................................................................................................... 48  124 
8.2.1 C
GM Calibration ........................................................................................................... 48  125 
8.2.2 System Failure  ............................................................................................................... 49  126 
8.2.3 Hypoglycemia Threshold Alert and Safety Protocol ..................................................... 49  127 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 7 OF 84 
 8.2.4 Hyperglycemia Threshold Alert and Safety Protocol .................................................... 49  128 
CHAPTER 9: TESTING PROCEDURES , QUESTIONNAIRES , AND FOCUS GROUPS  .................................... 51 129 
 Laboratory Testing ............................................................................................................... 51  130 
9.1.1 HbA1c: ........................................................................................................................... 51  131 
 Questionnaires ..................................................................................................................... 51  132 
9.2.1 P
edsQL Diabetes Module – Parent  ................................................................................ 51  133 
9.2.2 Pediatric Inventory for Parents ...................................................................................... 51  134 
9.2.3 INSPIRE Survey – Parent  .............................................................................................. 51  135 
9.2.4 Pittsburgh Sleep Quality Index (PSQI) – Parent ............................................................ 52  136 
9.2.5 Hypoglycemia Fear Survey- Parent (HFS -P) ................................................................. 52  137 
9.2.6 Hypoglycemia Confidence Scale ................................................................................... 52  138 
9.2.7 System Usability Scale (SUS) ....................................................................................... 52  139 
 Focus Groups ....................................................................................................................... 53  140 
CHAPTER 10: UNANTICIPATED PROBLEM , ADVERSE EVENT , AND DEVICE ISSUES REPORTING  ........ 54 141 
 Unanticipated Problems ..................................................................................................... 54  142 
 Adverse Events  .................................................................................................................. 54  143 
10.2.1 D
efinitions.................................................................................................................... 54  144 
10.2.2 Reportable Adverse Events .......................................................................................... 55  145 
10.2.3 Hypoglycemic Events .................................................................................................. 56  146 
10.2.4 Hyperglycemic/Ketotic Events .................................................................................... 56  147 
10.2.5 Relationship of Adverse Event to Study Device.......................................................... 57  148 
10.2.6 Severity (Intensity) of Adverse Events ........................................................................ 57  149 
10.2.7 Expectedness ................................................................................................................ 58  150 
10.2.8 Coding of Adverse Events ........................................................................................... 58  151 
10.2.9 Outcome of Adverse Events ........................................................................................ 58  152 
 Reportable Device Issues  ................................................................................................... 59  153 
 Timing of Event Reporting ................................................................................................ 59  154 
 Safety Oversight ................................................................................................................ 60  155 
 Stopping Criteria ................................................................................................................ 60  156 
10.6.1 P
articipant Discontinuation of Study Device ............................................................... 60  157 
10.6.2 Criteria for Suspending or Stopping Overall Study ..................................................... 61  158 
CHAPTER 11: MISCELLANEOUS CONSIDERATIONS  ................................................................................. 62 159 
 Drugs Used as Part of the Protocol .................................................................................... 62  160 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 8 OF 84 
 
 Collection of Medical Conditions and Medications .......................................................... 62  161 
 Prohibited Medications, Devices, Tr eatments, and Procedures ......................................... 62  162 
 Precautionary Medications, Treatments, and Procedures .................................................. 62  163 
 Prophylactic Medications, Treatments, and Procedures .................................................... 62  164 
 Rescue Medications, Treatments, and Procedures ............................................................. 63  165 
 Participant Compensation  .................................................................................................. 63  166 
 Participant Withdrawal ...................................................................................................... 63  167 
 Confidentiality  ................................................................................................................... 63  168 
CHAPTER 12: STATISTICAL CONSIDERATION  ......................................................................................... 64 169 
 Statistical and Analytical Plans .......................................................................................... 64  170 
 Statistical Hypotheses  ........................................................................................................ 64  171 
 Sample Size........................................................................................................................ 64  172 
 Efficacy Outcome Measures  .............................................................................................. 65  173 
12.4.1 P
rimary Efficacy Endpoint .......................................................................................... 65  174 
12.4.2 Secondary Efficacy Endpoints ..................................................................................... 65  175 
12.4.2.1 Secondary Efficacy Endpoints Included in Hierarchical Analysis ...................... 65  176 
12.4.2.2 Other Secondary Efficacy Endpoints ................................................................... 65  177 
12.4.3 CGM Metrics Calculations .......................................................................................... 66  178 
 Analysis Datasets and Sensitivity Analyses  ...................................................................... 67  179 
12.5.1 P
er Protocol Analyses .................................................................................................. 67  180 
12.5.2 Other Sensitivity Analyses ........................................................................................... 67  181 
 Analysis of the Primary Efficacy Endpoint ....................................................................... 68  182 
 Analysis of the Secondary Endpoints ................................................................................ 68  183 
12.7.1 H
ierarchical Analyses .................................................................................................. 68  184 
12.7.2 Other Endpoint Analyses ............................................................................................. 69  185 
 Safety Analyses .................................................................................................................. 70  186 
 Intervention Adherence...................................................................................................... 71  187 
 Protocol Adherence and Retention .................................................................................. 71  188 
 Baseline Descriptive Statistics  ......................................................................................... 71  189 
 Device Issues  ................................................................................................................... 72  190 
 Planned Interim Analyses  ................................................................................................ 72  191 
 Subgroup Analyses .......................................................................................................... 72  192 
 Multiple Comparison/Multiplicity  ................................................................................... 73  193 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 9 OF 84 
 
 Exploratory Analyses ....................................................................................................... 73  194 
 Extension Phase ............................................................................................................... 74  195 
12.17.1 E
xclusion of Ancillary Study Data ............................................................................ 75  196 
 Extended Use Period ........................................................................................................ 75  197 
CHAPTER 13: DATA COLLECTION AND MONITORING  ............................................................................ 76 198 
 Case Report Forms and Device Data  ................................................................................. 76  199 
 Study Records Retention ................................................................................................... 76  200 
 Quality Assurance and Monitoring .................................................................................... 76  201 
 Protocol Deviations............................................................................................................ 77  202 
CHAPTER 14: ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ............................................................ 78 203 
 Ethical Standard  ................................................................................................................. 78  204 
 Institutional Review Boards............................................................................................... 78  205 
 Informed Consent Process ................................................................................................. 78  206 
14.3.1 C
onsent Procedures and Documentation ..................................................................... 78  207 
14.3.2 Participant and Data Confidentiality ............................................................................ 78  208 
CHAPTER 15: ANCILLARY STUDY TO TEST CONTROL -IQ SYSTEM WITH MEAL BOLUS AND EXERCISE 209 
CHALLENGES  ............................................................................................................................................. 80 210 
 Objective  ............................................................................................................................ 80  211 
 Sample Size........................................................................................................................ 80  212 
 Eligibility  Criteria  .............................................................................................................. 80  213 
 Study Procedures ............................................................................................................... 80  214 
 Outcomes and Analysis Plan  ............................................................................................. 82  215 
Saf
ety Monitoring ...................................................................................................................... 83  216 
CHAPTER 16: REFERENCES  ....................................................................................................................... 84 217 
218 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 10 OF 84 
 LIST OF ABBREVIATIONS  219 
ABBREVIATION  DEFINITION  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CRF Case Report Form  
CGM Continuous Glucose Monitoring System  
CLC Closed -Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
CTR Control -to-Range  
DiAs Diabetes Assistant  
DKA Diabetic Ketoacidosis  
EC European Commission  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
ID Identification  
iDCL International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin-on -Board  
IQR Interquartile Range  
JDRF Juvenile Diabetes Research Foundation  
LGS  Low Glucose Suspend  
PLGS  Predictive Low Glucose Suspend  
POC Point -of-Care 
QA Quality Assurance  
QC Quality Control  
RBM Risk-Based Monitoring  
RCT Randomized Control Trial  
SC Standard of Care group  
SD Standard Deviation  
TDD Total Daily Dose  
UI User Interface  
 220 
221 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 11 OF 84 
 Signature Page  222 
Translation of the UV A Advanced Automated Insulin Delivery 223 
Systems to Clinical Care in Young Children: Glycemic Control, 224 
Regulatory Acceptance, and Optimization of Day to Day Use  225 
Protocol Identifying Number: PEDAP  226 
IND/IDE Sponsor: University of Virginia  227 
Version Number: 11 .0 228 
03 DEC  2021 229 
 
Protocol Chair   
Name, Institution  R. Paul Wadwa, M.D.  / University of Colorado – Barbara Davis Center  
Signature/Date   
 
Sponsor (IDE Holder)   
Name/Institution  Marc D. Breton , Ph.D. / University of Virginia  
Signature/Date   
 
Coordinating Center Director  
Name, Institution  John Lum, MS  / Jaeb Center for Health Research  
Signature/Date   
 
Medical Monitor   
Name, Institution  Roy Beck, MD, Ph.D . / Jaeb Center for Health Research  
Signature/Date   
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 12 OF 84 
 CLINICAL CENTER PRINCIPAL INVESTIGATOR STATEMENT OF 230 
COMPLIANCE  231 
Protocol Title:  The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized Controlled 232 
Comparison of the Control- IQ technology Versus Standard of Care in Young Children in 233 
Type 1 Diabetes  234 
Protocol Version/Date: 11 .0 / 03 DEC  2021 235 
I have read the protocol specified  above.  I n my formal capacity as a Clinical Center Principal 236 
Investigator, my duties include ensuring the safety of the study participants enrolled under my 237 
supervision and providing the Jaeb Center for Health Research , with complete and timely 238 
information, as outlined in the protocol.  It is understood that all information pertaining to the 239 
study will be held strictly confidential and that this confidentiality requirement applies to all 240 
study staff at this clinical center . 241 
This trial will be carried out in accordan ce with ICH E6 Good Clinical Practice (GCP) and as 242 
required by the following: United States (US) Code of Federal Regulations (CFR) applicable to 243 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 244 
CFR Part 812). 245 
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol 246 
will take place without prior agreement from the sponsor and documented approval from the 247 
Institutional Review Board (IRB), or other approved Ethics Committee, exc ept where necessary 248 
to eliminate an immediate hazard(s) to the trial participants.  249 
All key personnel (all individuals responsible for the design and conduct of this trial) have 250 
completed Human Participants Protection Training and Good Clinical Practice Training.  251 
Further, I agree to ensure that all staff members involved in the conduct of this study are 252 
informed about their obligations in meeting the above commitments. 253 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____ 254 
 dd mmm  yyyy  255 
Investigator’s Name: ____________________________________ 256 
Clinical Center Name/Number: _____________________________________ 257 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 13 OF 84 
 PROTOCOL SUMMARY  258 
PARTICIPANT AREA  DESCRIPTION  
Title The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized 
Controlled Comparison of the Control -IQ technology Versus Standard 
Care in Young Children in Type 1 Diabetes  
Précis A randomized controlled trial of at -home closed loop system vs . standard 
care (defined as either multiple daily injections of insulin [MDI ] or use of 
an insulin pump without hybrid closed-loop control capabilities [low -
glucose suspend or predictive low -glucose suspend functionality is 
permitted ]) in youth age 2 to <6 years  old. 
Investigational Device  t:slim X2 with Control-IQ and Dexcom G6 system  
Objectives  The objective of the study is to assess efficacy , quality of life,  and safety 
of a closed loop control  (CLC) system (t:slim X2 with Control-IQ 
Technology) in a randomized controlled trial  with partial crossover . 
Study Design  First phase: a 13 -week parallel group r andomized clinical trial with 2 :1 
randomization to intervention with the closed loop system vs. standard care (SC); Second Phase: foll owing the RCT, a 13-week period where the 
Standard Care (SC) group will transition to use CLC and the experimental arm will extend the use of CLC for the same period . After 26 weeks, 
participants may continue using CLC for an additional Extended Use 
period . A subset of participants will be invited to join an optional 
exercise/meal challenge ancillary study.  
Number of Clinical Centers  ~3 US clinical centers  
Endpoint s Efficacy  
The primary outcome for the RCT  is time in target range 70 -180 mg/dL  
(TIR) measured by CGM in CLC group vs. SC  group over 13 weeks  
The primary outcome for the extension phase  assessed separately for each 
treatment group  is change in TIR comparing extension phase with RCT 
phase .  
 
Quality of Life  
Patient -reported outcome questionnaires will be completed.  
 
Safety  
The key safety outcomes are severe hypoglycemia and ketoacidosis.  
Population  Inclusion Criteria  
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least 6 months and using insulin for at least 6 months  
2. Familiarity and use of a carbohydrate ratio for meal boluses.  
3. Age ≥2 and < 6 years old  
4. Living with one or more parent/legal guardian knowledgeable about 
emergency procedures for severe hypoglycemia and able to contact emergency services and study staff.  
5. Investigator has confidence that the parent can successfully operate all study devices and is capable of adhering  to the protocol  
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) 
or aspart (Novolog) during the study for participants using a study-
provided Tandem pump during the st udy. 
7. Total daily insulin dose (TDD) at least 5 U/day  
8. Body weight at least 20 lbs  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 14 OF 84 
 PARTICIPANT AREA  DESCRIPTION  
9. Willingness not to start any new non -insulin glucose -lowering agent 
during the course of the trial  
10. Participant and parent(s)/guardian(s) willingness to participate in all 
training sessions as directed by study staff.  
11. Parent/guardian proficient in reading and writing English  
12. Live in the United States, with no plans to move outside the United 
States during the study period  
 
Exclusion Criteria   
1. Concurrent use of any non-insulin g lucose -lowering agent (including 
GLP -1 agonists, Symlin, DPP -4 inhibitors, SGLT -2 inhibitors, 
sulfonylureas).  
2. Hemophilia or any other bleeding disorder  
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the last 3 months  
4. History of >1 DKA event in the last 6 months not related to illness, infusion set failure, or initial diagnosis  
5. History of chronic renal disease or currently on hemodialysis  
6. History of adrenal insufficiency  
7. Hypothyroidism that is not adequately treated 
8. Use of oral or injectable steroids within the last 8 weeks  
9. Known, ongoing  adhesive intolerance  
10. Plans to receive blood transfusions or erythropoietin injections during the course of the study  
11. A condition, which in the opinion of the investigator or designee,  
would put the participant or study at risk  
12. Currently using any closed -loop system , or using an insulin pump 
that is in compatible with use of the study CGM  
13. Participation in another pharmaceutical or device trial at the time of enrollment or during the stud y 
14. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first -
degree relative who is directly involved in conducting the clinical trial 
Sample Size  Up to 150 screened  participants with the goal of randomizing 10 2 
participants.  
Treatment Groups  • Intervention Group: t:slim X2 with Control -IQ Technology and 
Study CGM.  
• Control Group: Standard care ( SC) - defined as either multiple daily 
injections of insulin ( MDI ) or use of a n insulin pump without  hybrid 
closed -loop control capabilities (low -glucose suspend or predictive 
low-glucose  suspend  functionality is permitted)  in conjunction with 
study CGM  
All participants  will be offer ed to extend the study for a n additional 13 
weeks , with the SC group switching to the t:slim X2 with Control-IQ  
System a fter the 13-week  RCT period . After 26 weeks, participants may 
continue using CLC for an additional Extended Use p eriod.   
Participant Duration  ~26-32 weeks  for RCT and Extension Phase , depending on duration of 
run-in phase; up to an additional ~7 months in Extended Use period  
Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  Eligible participants not currently using an insulin pump and Dexcom G5 or Dexcom G6 CGM 
with minimum data requiremen ts will initiate a run -in phase of 2 to 6 
weeks that will be customized based on whether the participant is already 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 15 OF 84 
 PARTICIPANT AREA  DESCRIPTION  
a CGM user.  Participants who skip or successfully complete the run -in 
will be randomly assigned 2 :1 to an intervention using  Tandem t:slim X2 
with Control-IQ Technology  or the standard care control group using 
existing insulin therapy in conjunction with study CGM . All participants 
will  continue their participat ion by using the t:slim X2 with Control-IQ 
system in an  Extension Phase. [ Figure 1] After 26 weeks, participants 
may continue using CLC for an additional Extended Use p eriod  through 
no later than July 31, 2022. A subset of participants will complete an 
optional exercise/meal challenge ancillary study.  
 259 
  260 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 16 OF 84 
  261 
Figure 1: Study Design: Participants Randomized 2:1 Control- IQ Control (CLC) vs. 262 
Standard Care (SC) Groups . Extension phase with partial crossover of SC G roup 263 
switching to use Control- IQ. Subsequent Extended Use period  through no later than July 264 
31, 2022. 265 

 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 17 OF 84 
 SCHEMATIC OF STUDY DESIGN  266 
 267 
Figure 2: Overview of Study Design   268 
Screening/ Enrollment  
•Eligibility assessment and informed consent  
•Device download and adherence assessment for current CGM user  
 
CGM Placement/Training  
2-6 Week Run-In with  home use of study CGM   
       
Run-in Review  
Reassess Eligibility  
 
Randomization  
 
Eligible  
To Skip 
Run-In*? 
No 
Yes 
*Current u se of  Dexcom G5  or G6 CGM wit h readings captured on at least  
11 out of the previous 14 days  
13 Weeks - End of RCT; start of Extension Phase - 
all participants use Control -IQ 
26 Weeks - End of Extension Phase  
13-Week RCT  
       
13-Week Extension Phase  
       
End of Study  
Extended Use P eriod through July 31, 2022  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 18 OF 84 
  269 
Figure 3:  Schematic of Study Design (Post-Randomization through 26 Weeks ) 270 
Randomization  
 
Week 2 Videoconference or Visit  
Refresher training on devices  
Phone Contact:  Week 10  
Videoconference or Clinic Visit: Weeks 6, 13 
 
 
Study pump 
training and 
transition to  
study pump 
Primary Outcome  
 (13 weeks)  
CLC Group  
 SC Group  
Continued use of study 
closed -loop system  
 
Continued use of study 
CGM along with current 
insulin delivery (MDI or 
personal pump)  
Continued use of study CGM along with 
current insulin delivery  
Week 1 Phone Contact  
System  data assessment  
Study pump training and transitions as shown 
above for CLC Group , then use of updated 
Control- IQ system for 13 weeks  
Videonconference/ Phone Contact: Day 3;  
Phone Contact: Weeks 14, 23;  
Videoconference  or Clinic Visit : Weeks 15, 19  
  
End of Extension Phase  (26 weeks)  
Transition to updated Control -IQ closed -
loop system for 13 additional weeks. 
Training will be provided on new features.  
Videonconference/ Phone Contact: Day 3;  
Phone Contact: Weeks 14, 23;  
Videoconference or Clinic Visit : Weeks 15, 19  
  
 
 MDI User?  
Study pump training and 
transition from MDI to pump 
Yes 
 No 
3-Day Videoconference or Call  
Pump settings adjustment  
Week 1 Phone Contact  
CGM data assessment  
CLC Group  
 SC Group  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 19 OF 84 
  271 
Figure 4:  Schematic of Study Design (Extended Use Period ) 272 
Study pump retraining visit and 
transition back to study pump 
 
No 
 Yes 
Gap between 26 -Week visit and 
start of Extended Use phase? 
Continued use of study 
closed -loop system  
Continued use of study 
closed -loop system  
Videoconference /Phone Contact  
Day 3; Week 1  
Every 13 Weeks  
Videoconference/Clinic Visit  
Final Visit; E nd of Study * 
* Final Visit to occur no later than July 31,  2022  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 20 OF 84 
  273 
1 Only for participants on MDI at enrollment  assigned to the CLC group   274 
 275 
Table 1. Schedule of Study Visits and Procedures  (through 26- Week Visit)  276 
  277  Pre Pre 0 3d1 1w 2w 6w 10w 13w 13w + 
3d 14w 15w 19w 23w 26w 
Visit (V) , 
Videoconference (VC),  
or Phone (P)  VC/V VC/V VC/V VC/ 
P P VC/V  VC/
V P VC/
V VC/ 
P P VC/
V VC/
V P VC/
V 
Comment  Screen/
Enroll  Run- in Rand              
Eligibility Assessment  X X X             
HbA1c (Central lab)    X      X      X 
Device Data 
download (s) X X X X X X X X X X X X X X X 
Review diabetes 
management and AEs   X X X X X X X X X X X X X X 
Questionnaires as 
defined in section  9.2 X        X      X 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 21 OF 84 
  278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
1 Participants are eligible to initiate Extended Use period if they completed the 26 -Week Visit within the prior 4 months  287 
2 Only for participants who had a gap between the 26 -Week Visit and the initiation of the Extended Use period during  288 
which they stopped use of the study pump and reverted to MDI or personal pump insulin therapy  289 
 290 
Table 2. Schedule of Study Visits and Procedures  (Extended Use Period ) 291 
 292 
 293 Days/Weeks after  
26-Week Visit =>  02 3d2 1w2 13w 26w, 39w, 
etc. Final 
Visit  
Visit (V) , 
Videoconference (VC),  
or Phone (P)  VC/V VC/ 
P VC/ 
P VC/V  VC/V  VC/V  
Eligibility Assessment1,2 X      
Study Pump Retraining2 X      
HbA1c (Central lab)     X X  
Device Data download (s)  X X X X X 
Review diabetes 
management and AEs   X X X X X 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 22 OF 84 
 Chapter 1:  Background Information 294 
 Introduction 295 
The Tandem X2 insulin pump with Control -IQ Technology is a third- generation closed -loop 296 
control (CLC) system retaining the same control algorithm that was initially tested by UVA’s DiAs 297 
system and then implemented in the inControl system (TypeZero Technologies, Inc.). 298 
The system has received FDA approval for  use in individuals ≥ 6 years old following a pair of 299 
pivotal trials that demonstr ated the system’s safety and efficacy, first in participants ≥1 4 years old 300 
(1) and then subsequently in participants ≥ 6 years old  (2).  301 
Closed -Loop Control System 302 
The Closed -Loop Control System contained in t -slim X2 with Control -IQ Technology is described  303 
in Master File MAF -2032/A008. Control -IQ Technology is derived from inControl previously 304 
described in IDE# G160097, G160181, G150240 and G140169/S010. The CLC is an “artificial 305 
pancreas” (AP) application that uses advanced closed loop control algorithms to automatically 306 
manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to 307 
keep blood glucose in a targeted range. The system components include the  t:slim X2 with 308 
Control-IQ Technology and the Dexcom CGM G6. 309 
 310 
Figure 5. t:slim X2 with Control -IQ and Dexcom G6 system 311 
 Rationale 312 
The objective of this randomized clinical trial is to assess the efficacy and safety of the Control - 313 
IQ closed loop system over a 13- week  period compared with standard care. In addition, the data 314 
from this trial may be used for subsequent regulatory submiss ions for this system  in the age group 315 
studied. 316 
The extension phase will allow for additional exposure time to the Tandem t:slim X2 with Control- 317 
IQ Technology and evaluation of the SC arm after crossing over to use Control -IQ for a 13-week  318 
period.  319 

 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 23 OF 84 
 
 Potentia l Risks and Benefits of the Investigational Device 320 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 321 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 322 
risk in participants with type 1 diabetes and participants will be monitored for these events . 323 
 
 324 
1.3.1.1 Potential Risks and Benefits of the CLC System  325 
Even though the study system has been tested prior to this study, there is still a risk that parts of 326 
the system may not function properly. The following are possible reasons the system may deliver 327 
too much insulin or incorrectly stop insulin delivery: 328 
• CGM sensor reads higher or lower than the actual glucose level which increases risk for 329 
hypoglycemia and hyperglycemia with automated insulin delivery s ystem; 330 
• Device malfunctions that could produce a suspension of insulin delivery or over delivery 331 
of insulin. 332 
1.3.1.2 Risk of Hypoglycemia 333 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 334 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less 335 
than it would be as part of daily living.  Symptoms of hypoglycemia can include sweating, 336 
jitteriness, and not feeling well.  Just as at home, there is the possibility of fainting or seizu res 337 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 338 
hypoglycemia.  A CGM functioning poorly and significantly over -reading glucose values could 339 
lead to inappropriate insulin delivery. 340 
1.3.1.3 Risk of Hyperglycemia  341 
Hyperglyc emia and ketonemia could occur if insulin delivery is attenuated or suspended for an 342 
extended period or if the pump or infusion set is not working properly.  A CGM functioning poorly 343 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin 344 
delivery. 345 
1.3.1.4 Fingerstick Risks  346 
At various times s everal drops  of blood will be removed by fingerstick. This is a standard method 347 
used to obtain blood for routine hospital laboratory tests.  Pain is common at the time of lancing.  348 
In ab out 1 in 10 cases, a small amount of bleeding under the skin will produce a bruise.  A small 349 
scar may persist for several weeks.  The risk of local infection is less than 1 in 1000.  This should 350 
not be a significant contributor to risks in this study as fi ngersticks are part of the usual care for 351 
people with diabetes. 352 
1.3.1.5 Subcutaneous Catheter Risks (CGM)  353 
Participants using the CGM will be at low risk for developing a local skin infection at the site of 354 
the sensor needle placement.  If a catheter is left under the skin for more than 24 hours , it is possible 355 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 24 OF 84 
 to get an infection where it goes into the skin, with swelling, redness and pain.  There may be 356 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk). 357 
Study staff should verbally alert the participant that on rare occasions, the CGM may break and 358 
leave a small portion of the sensor under the skin that may cause redness, swelling or pain at the 359 
insertion site.  The participant should be further instructed to notify the study coordinator 360 
immediately if this occurs.  361 
1.3.1.6 Risk of Device Reuse  362 
The study CGM system is labeled for single use only. The sensor (the component of the system 363 
that enters the skin) will be single use only. The receiver, if used, is a hand- held devi ce. The 364 
transmitter and receiver may be reused during the study after cleaning the device using a hospital - 365 
approved cleaning procedure. The transmitter is attached to the sensor but does not enter the skin . 366 
Participants will be informed that FDA or relevan t national authorities have approved these devices 367 
for single use and that by using them among multiple patients, bloodborne pathogens (i.e. Hepatitis 368 
B) may be spread through the use of multiple users. 369 
The study insulin pump is labeled for single -patient use. During the study, this device may be 370 
reused after cleaning adhering to a hospital -approved cleaning procedure. All infusion set 371 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.)  372 
Participants will be info rmed that FDA or relevant national authorities typically approve the insulin 373 
pump device for single use and that by using them among multiple patients, bloodborne pathogens 374 
(i.e. Hepatitis B) may be spread through the use of multiple users. 375 
The study blood glucose meter and blood ketone meter are labeled for single -patient use. 376 
During the study, only one person can use each device as there are rare risks that bloodborne 377 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users. 378 
1.3.1.7 Questionna ires and Focus Groups  379 
As part of the study, parents of participants will complete questionnaires which include questions 380 
about their private attitudes, feelings and behavior related to the investigational equipment as well 381 
as managing diabetes.  Parents may also participate in a focus group session to explore their 382 
feelings about using the closed- loop system. It is possible that some people may find these 383 
questionnaires or focus groups to be mildly upsetting. Similar questionnaires and focus groups 384 
have been used in previous research and these types of reactions have been uncommon. 385 
1.3.1.8 Other Risks  386 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 387 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  388 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 389 
etc.) will be tried, sites will be rotated frequently, and a mild topical steroid cream or other 390 
medication may be required. 391 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 392 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 393 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 25 OF 84 
 cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 394 
topical antibiotics can be used.  The risk of skin problems could be greater if you use a sensor for 395 
longer than it is supposed to be used.  Therefore, participants  (and parents)  will be carefully 396 
instructed about proper use of the sensor. 397 
Data downloaded from the CGM, pump, and the home glucose and ketone meter will be collected 398 
for the study as measures of diabetes self -management behaviors.  Some people 399 
may be uncomfortable with the researchers' having such detailed information about their daily 400 
diabetes habits.  401 
 
 402 
One purpose of this research is to reduce the frequency of hypoglycemia and severe hypoglycemic 403 
events. Hypoglycemia is the number one fear of many individuals and families with someone who 404 
has type 1 diabetes and this fear often prevents optimal glycemic control.  405 
It is expected that this protocol will yield increased knowledge about using an automated 406 
closed -loop system  to control the glucose level and is intended to develop data to support future 407 
device approval  in the age group studied. The individual participant may not benefit from study 408 
participation.  409 
 
 410 
Based on the facts that (1) children with diabetes experience mild hypoglycemia and 411 
hyperglycemia frequently as a consequence of the disease and its management, (2) the s tudy 412 
intervention involves periodic automated insulin dosing that may reduce the likelihood of 413 
hypoglycemia, and periodic automated attenuation of insulin delivery that may reduce the 414 
likelihood of hyperglycemia, (3) if any, hypo and/or hyperglycemia occur , mitigations are in place, 415 
and have been tested in prior studies using the investigational device system in the home setting, 416 
that limit the likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (4) 417 
rapid reversal of hypoglycemia and hyperglycemia can be achieved, it is the assessment of the 418 
investigators that this protocol falls under DHHS 45 CFR 46.405 and 21 CFR 50.52 as a clinical 419 
investigation involving greater than minimal risk but presenting the prospect of direct benefit to 420 
individual subjects . In addition, it is the belief of the investigators that this study also presents 421 
prospect of general benefit to others with diabetes. 422 
 General Considerations  423 
The study is being conducted in compliance with the policies described in the  study policies 424 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with the 425 
protocol described herein, and with the standards of Good Clinical Practice (GCP). 426 
There is no restriction on the number of participants to be enrolled by each clinical center toward 427 
the overall recruitment goal.  428 
The protocol is considered a significant risk device study, due to the fact that the closed loop 429 
system is experimental in the population under study.  Therefore, an investigational  device 430 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 26 OF 84 
 exemption (IDE) from the U.S. Food and Drug Administration (FDA) is required to conduct the 431 
study. 432 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 27 OF 84 
 Chapter 2:  Study Enrollment and Screening  433 
 Participant Recruitment and Enrollment  434 
Enrollment will proceed with the goal of having 10 2 participants randomized.  A maximum of 150 435 
individuals may be enrolled into screening for the study in order to achieve this goal. 436 
Study participants will be recruited at ~3 clinical centers in the United  States without regard to 437 
gender, race, or ethnicity.  There is no restriction on the number of participants to be enrolled by 438 
each clinical center toward the overall recruitment goal. 439 
The study team will make every effort to have the following minimum numbers of participants 440 
complete the trial in the specified subgroups at the time of enrollment: 441 
• Approximately two -thirds of the participants with most recent available HbA1c ≥  7.5% 442 
• Approximately 30 participants in the age range ≥ 24 months to <48 months 443 
• At le ast 20% of participants who are on multiple daily injections (MDI) rather than pump 444 
 
 445 
Potential eligibility may be assessed as part of a routine -care examination.  Before completing any 446 
procedures or collecting any data that are not part of usual care, electronic informed consent will 447 
be obtained. 448 
A parent/legal guardian (referred to subsequently as “parent”) will be provided with the Informed 449 
Consent Form to read and will be given the opportunity to ask questions  either via 450 
phone/videoconference or by mail or email. If the parent and child are interested in the study, the 451 
investigator will schedule a virtual or in- person visit to discuss study, and if the parent and child 452 
agree to participate, the Informed Consent Form will be electronically signed through the JCHR 453 
website .  A copy of the electronically signed consent form can be printed by  the parent and another 454 
copy will be printed by the site to add to the participant’s study record. 455 
As part of the informed consent process, the parent will be asked to sign an authorization for release 456 
of personal information. This may be done electronicall y with the consent, or on paper if the site 457 
requires their own process. The investigator, or his or her designee, will review the study- specific 458 
information that will be collected and to whom that information will be disclosed.  After speaking 459 
with the parent , questions will be answered about the details regarding authorization. 460 
A participant is considered enrolled when the informed consent form  has been  electronically  461 
signed and HIPAA authorization has been provided. 462 
 Participant Inclusion Criteria  463 
Individuals must meet all of the following inclusion criteria in order to be eligible to participate in 464 
the study. 465 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 28 OF 84 
 1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least 6 months  466 
and using insulin for at least 6 months  467 
2. Familiarity a nd use of a carbohydrate ratio for meal boluses. 468 
3. Age ≥ 2 and <6 years  old 469 
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures for 470 
severe hypoglycemia and able to contact emergency services and study staff . 471 
5. Investigator has confidence that the parent can successfully operate all study devices and is 472 
capable of adhering to the protocol 473 
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use 474 
no other insulin besides lispro (Humalog) or aspart (Novolog) during the study for participants 475 
using a study-provided Tandem pump during the study. 476 
• Study will not be providing insulin; therefore, participants will need to have access to 477 
either lispro or aspart 478 
7. Total daily insul in dose (TDD) at least 5 U/day  479 
8. Body weight at least 20 lbs 480 
9. Willingness not to start any new non- insulin glucose -lowering agent during the course of the 481 
trial ( see section 2.3) 482 
10. Participant and parent(s)/guardian(s) willingness to participate in all training sessions as 483 
directed by study staff.  484 
11. Parent/guardian proficient in reading and writing English 485 
12. Live in the United States, with no plans to move outside the United States during the study 486 
period 487 
 Participant Exclusion Criteria  488 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 489 
participation.  490 
1. Concurrent use of any non- insulin glucose -lowering agent (including GLP -1 agonists, Symlin, 491 
DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 492 
2. Hemophilia or any other bleeding disorder 493 
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the last 3 494 
months 495 
4. History of >1 DKA event in the last 6 months not related to illness, infusion set failure, or 496 
initial diagnosis  497 
5. History of chronic renal disease or currently  on hemodialysis 498 
6. History of adrenal insufficiency 499 
7. Hypothyroidism that is not adequately treated  500 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 29 OF 84 
 8. Use of oral or injectable steroids within the last 8 weeks   501 
9. Known, ongoing  adhesive intolerance 502 
10. Plans to receive blood transfusions or erythropoietin injections during the course of the study 503 
11. A condition, which in the opinion of the investigator or designee, would put the participant or 504 
study at risk (specified in the study procedure  manual) ; the investigator will take into account 505 
the participant’s HbA1c level, compliance with current diabetes management, and prior acute 506 
diabetic complications  507 
12. Currently using a ny closed -loop system , or using a n insulin pump that is incompatible with 508 
use of the study CGM 509 
13. Participation in another pharmaceutical or device trial at the time of enrollment or during the 510 
study 511 
14. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., 512 
or having a direct supervisor at place of employment who is also directly involved in 513 
conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first -degree 514 
relative who is directly involved in conducting the clinical trial 515 
 Eligibility Assessment and Baseline Data Collection  516 
Potential participants will be evaluated for study eligibility through the elicitation of a medical 517 
history and local laboratory testing as needed in the judgment of the investigator (as part of usual 518 
care).  519 
The screening visit and subsequent scheduled study visits may be conducted virtually via 520 
videoconference at the discretion of the study investigator, for example due to institutional 521 
restrictions or the participant or investigator’s preference for a remote visit. Study staff will 522 
discuss the feasibility of conducting virtual visits with each participant and provide support as 523 
needed to ensure adequate access. The screening visit must be completed within 28 days of 524 
participant enrollment.  525 
 Historical Information  526 
A history will be elicited from the parent and extracted from available medical records with 527 
respect to the participant’s diabetes history, current diabetes management, other past and current 528 
medical problems, past and current medications, and drug all ergies .   529 
 Screening Testing and Procedures  530 
At the Screening Visit the following procedures will be performed: 531 
• Informed consent process 532 
• Assessment of eligibility  533 
• Contact information (retained at the clinical center and not entered into study database)  534 
• Demog raphics (date of birth, sex, race and ethnicity) 535 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 30 OF 84 
 • Measurement of height/weight 536 
o If the visit is conducted virtually, a verbal report of the participant’s weight and 537 
verbal report of height will be acceptable. A scale will be provided for 538 
participants who do not already have a scale at home.  539 
• Determination of most recent HbA1c level from  medical records or verbal report  540 
• Participants ’ parents  will complete a set of baseline questionnaires, described in 541 
section 9.2. 542 
 Screen Failures  543 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 544 
date per investigator discretion. 545 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 31 OF 84 
 Chapter 3:  CGM Run- In Phase  546 
 CGM Run -in Phase Overview  547 
This phase must begin (supplies shipped) within 3 days of completion of the Screening visit. The 548 
purpose of this CGM run-in phase  is to 1) assess compliance with study procedures  and 2) to 549 
introduce the study CGM to study participants without current use of a Dexcom CGM.  550 
Participants who currently use a Dexcom G5 or G6 with CGM data captured on at least 11 out of 551 
the previous 14 days prior to the time of enrollment can skip the run- in phase. Participants who do 552 
not currently use a Dexcom G5 or G6 CGM, or who do use that CGM but have readings captured 553 
on fewer  than 11 out of the previous 14 days prior to time of enrollment , will be required to 554 
participate in the CGM run -in phase. 555 
Participants and their parent(s) will receive training on the study CGM as detailed below. This will 556 
be an unblinded use of the study CGM.  557 
 Initiation of CGM  558 
Study CGM supplies will be provided to the participant  either in -person at the clinic, or via 559 
deliv ery by other means (personal delivery, overnight shipment, etc.).   560 
Once the supplies have been received, the participant  and parent  will be instructed to use the study 561 
CGM on a daily basis. Participants using a personal CGM prior to the study will discontinue the 562 
personal CGM beginning in this period. 563 
 
 564 
CGM t raining (in-person or via videoconference) will be provided by a qualified trainer  to 565 
participants not currently using a personal CGM identical to the study CGM as to how to use it in 566 
real-time to make management decisions and how to review the data after an upload for 567 
retrospective review. The participating child will participate in training sessions to the degree 568 
judged appropriate by the parent and trainer. CGM training will include: 569 
• Instruction on how to insert the sensor and transmitter, including observation/supervision 570 
of placement of a sensor  571 
• Instruction on how to calibrate the CGM unit, if needed  572 
• Guidance on accessing  the CGM trace, either through a manufacturer -provided software 573 
app or via a study- provided CGM receiver unit,  or via a personal insulin pump if 574 
participants  use a pump that integrates with the study CGM  575 
• Parents will be asked to perform fingerstick blood glucose measur ements in accordance 576 
with the labeling of the study CGM device 577 
A copy of the study CGM user’s guide will be provided to the participant’s parents. 578 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 32 OF 84 
 
 Blood G lucose and K etone T esting  579 
Participants will receive supplies for blood glucose and ketone testing. 580 
• Blood glucose testing 581 
o Participants will be provided with a study blood glucose meter, test strips, and standard 582 
control solution to perform quality control (QC) testing at home per manufacturer 583 
guidelines. 584 
o All study blood glucose meters will be QC tested with control solution if available prior to 585 
dispensation and during all office visits.  A tested meter will not be used in a study if it 586 
does not read within the target range at each concentration per manufacturer labeling.   587 
o Participants will be reminded to use the study blood glucose meter for all fingerstick BGs 588 
during the study. 589 
o Participants will be given guidelines for treatment of low or high blood glucose. 590 
• Blood ketone testing 591 
o Participants will be provided with a study blood ketone meter, test strips, standard control 592 
solution to perform QC testing at home per manufacturer guidelines, and 593 
software/hardware needed to download meter datafiles. 594 
o All study blood ketone meters will be QC tested with control solution if available prior to 595 
dispensation and dur ing all office visits.  A tested meter will not be used in a study if it 596 
does not read within the target range at each concentration per manufacturer labeling.  597 
o Participants will be instructed to perform blood ketone testing as described in section  7.1.6. 598 
o Participants will be given guidelines for treatment of elevated blood ketones 599 
• Participants will be required to have glucagon at home. Participants who currently do not have 600 
one will be given a prescription for glucagon (either emergency kit or nasal glucagon per 601 
investigator discretion for participants over 4 years of age). 602 
 Assessment of Successful Completion of the Run -in Phase  603 
Enrolled participants will have a follow -up visit or videoconference  approximately 14 days after 604 
initiation of the run -in phase to  assess progress or successful completion of the phase.  If needed, 605 
one or more interim visits or videoconference/ phone contacts may occur to assist the participant 606 
with any CGM  use issues. P rocedures will include downloading of the study CGM data and the 607 
following: 608 
Assessment of compliance with the use of CGM for at least 11 out of the prior 14 days 609 
Assessment of skin reaction in areas where a CGM sensor was worn or other safety issues 610 
associated with CGM use 611 
Assessment of eligibility to continue to the randomized control trial ( RCT ) phase of the study 612 
 613 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 33 OF 84 
 Participants Using a Personal CGM at Enrollment 614 
Participants who had currently been using a personal CGM at the time of enrollment (but did not 615 
meet requirements to skip run- in) and satisfy the CGM use criteria above without any major  safety 616 
issues and otherwise meet study eligibility requirements can be randomized .  617 
Participants who fail to meet the minimum CGM use requirement, or who the investigator believes 618 
may benefit from an extension of the CGM run- in period, may at the investigator’s discretion be 619 
allowed  to continue CGM run- in for a maximum of two  additional 2- week period s. These 620 
participants will have a follow -up visit  or videoconference  approximately 14 days  after each prior 621 
assessment for a reassessment using  the same procedures as described above.  622 
Participants who do not meet CGM use requirements after three 2- week periods of CGM run- in or 623 
otherwise fail to meet study eligibility requirements will be withdrawn from the study.  624 
Participants Not Using a Personal CGM at Enrollment  625 
Participants who had not currently been using a personal CGM at the time of enrollment will be 626 
assessed as described above. If there are no major safety issues and the investigator believes that 627 
the participant will remain  adherent to use  of the study CGM, the participant will be asked to 628 
continue the run- in phase for an additional 2- week period to establish  baseline glycemic control 629 
while using the study CGM . These participants will have a follow -up visit or videoconference  630 
approximately 14 days for a second follow -up visit with the same visit procedures as described 631 
above. 632 
Participants who fail to meet the minimum CGM use requirement  at the second follow -up, or who 633 
the investigator believes may benefit from a  further extension of the CGM run- in period, may at 634 
the investigator’s discretion be allowed to continue CGM run- in for one additional 2 -week period . 635 
These participants will have a follow-up visit or videoconference approximately 14 days after the 636 
second follow-up visit for a reassessment using the same procedures as described above.  637 
Participants who do not meet CGM use requirements after three 2 -week  periods of CGM run- in or 638 
otherwise fail to meet study eligibility requirements will be withdrawn from the study.  639 
 Optimization of Insulin Therap y 640 
Data will be obtained from CGM and/or pump downloads prior to  CGM run -in review contact s. 641 
Adjustments to pump settings (basal rates, correction factor, insulin- to-carbohydrate ratio, etc.) or 642 
injection strategies will be made in response to major trends observed in the CGM data, with 643 
flexibility for clinicians to adhere to guidelines and prac tices established at each individual practice 644 
rather than a fixed set of heuristics for all clinical centers . 645 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 34 OF 84 
 Chapter 4:  Randomization Visit  646 
 Visit  Timing  647 
The visit, which may be in- clinic or virtual,  may occur on the same day as the Screening or Run- 648 
in Review Visit, or on a subsequent day. If deferred, the randomization visit should occur no more 649 
than 14 days after successful completion of the run- in phase  or within 14 days of screening if run- 650 
in is skipped. 651 
 
 652 
Eligible participants will b e randomly assigned to one of two treatment groups in a 2:1 ratio: 653 
1. Control- IQ Closed -Loop Control ( CLC ) Group  654 
2. Standard C are (SC) Group  655 
The participant’s randomization group assignment is determined by completing a Randomization 656 
Visit case report form on the study website. The randomization list will use a permuted block 657 
design, stratified by clinical center.  658 
The participant will be included in the data analysis regardless of whether or not the protocol for 659 
the assigned randomization group is followed.  Thus, the investigator must not randomize a 660 
participant until he/she is convinced that the participant/parent will accept assignment to either 661 
of the two groups. 662 
It was decided that it was more important to stratify randomization by clinical center  than by 663 
factors such as baseline time in range, HbA1c, or device use since these factors will be easier to 664 
adjust for in analysis than will clinical center . 665 
 
 666 
A capillary blood sample will be obtained for baseline HbA1c determination . Capillary collection 667 
supplies will be provided to the participant within 3 days of randomization. This may occur either 668 
in-person at the clinic, or via delivery by other means (personal delivery, overnight shipment, etc.).   669 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 35 OF 84 
 Chapter 5:  Main Study Procedures  670 
 Visit  and Contact Schedule  671 
During the RCT period, visits and contacts will be scheduled as outlined in Table 3 below: 672 
Table 3: RCT Visit and Phone Contact Schedule  673 
Target Day/Week  Contact Type1 Target/ Allowable Window  
(around Target Day/Week)  
3 days2 VC/P  ± 2 days  
1 week  P ± 2 days  
2 weeks  VC/V ± 4 days  
6 weeks  VC/V ± 7 days  
10 weeks  P ± 7 days  
13 weeks  VC/V ± 7 days  
1 Contact Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by 674 
Videoconferences or Clinic Visits and Videoconferences may be replaced by Clinic Visits at investigator discretion  675 
2 Only for participants on MDI at enrollment assigned to the CLC  group ; timing will be with respect to the start of home use of 676 
the study system, rather than with respect to the start of the RCT 677 
Additional contacts or visits may occur as needed. 678 
 CGM Initiation and Training  679 
Participants who skipped CGM run-in will be provided with study CGM supplies and training as 680 
described in section 3.2 and instructed to use the study CGM on a daily basis. Participants 681 
currently using a personal CGM identical to the study CGM may sk ip the training. 682 
Provision of CGM supplies and training should be completed  within 3 days of randomization. 683 
 Procedures for the CLC Group  684 
The study pump, associated supplies , and training will be provided to participants assigned to the 685 
CLC group within 3 days of randomization. Dispensation of supplies may occur either in -person 686 
at the clinic, or via delivery by other means (personal delivery, overnight shipment, etc.). 687 
 
 688 
Parents of participants will rec eive study pump training by a qualified trainer. The participating 689 
child will participate in training sessions to the degree judged appropriate by the parent and 690 
trainer.  Pump training (in -person or via videoconference) will be provided by a qualified trainer 691 
to all CLC Group participants. 692 
Parents  will be fully instructed on the study insulin pump. The trainer will discuss differences from 693 
the participant’s  personal pump, if applicable, in important aspects such as calculation of insulin 694 
on board and correction boluses  and optional additional topics such as : infusion site initiation, 695 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 36 OF 84 
 cartridge/priming procedures, setting up the pump, charging the pump, navigation through menus, 696 
bolus procedures including stopping a bolus, etc. 697 
Parents will be instructed to change the study insulin pump infusion set at least once every 3 days 698 
or per manufacturer guidelines, whichever is shorter. 699 
Parent s will be trained to use the bolus calculator following the standard t:slim X2 training if they 700 
are not alre ady using the t:slim X2 bolus calculator. Parent/guardians with prior 701 
education/experience with using this bolus calculator will be offered refresher training. 702 
• The study team will assist the parent  in study pump infusion site initiation and will start 703 
the participant on the study pump. The study pump will be programmed with the 704 
participant’s usual basal rates and pump parameters , if applicable. The participant’s 705 
personal pump, if any, will be removed. 706 
• The parent will be supervised with the study pump during at least one meal or snack bolus 707 
to ensure participant understanding of the pump features. 708 
• The parent  will be encouraged to review the literature provided with the pump and infusion 709 
sets after the training is completed.  710 
• The parent will be trained on severe hypoglycemia emergency procedures including 711 
removal of the study pump and administration of glucagon. 712 
Pump training specific to the Control-IQ Technology functions will include: 713 
• How to turn on and off Control-IQ technology. 714 
• How to understand when Control- IQ is increasing or decreasing basal rates.  715 
• How to administer a meal or correction bolus es 716 
• What to do when exercising while using the system 717 
• How to enable the sleep function and set the sleep schedule 718 
• The parent will be assessed for understanding of the system interface and how to react to 719 
safety/alert messages.  720 
The parent  will be given a User Guide as a reference.  721 
 
 722 
For MDI participants being started on the study pump, a n initial basal insulin profile will be 723 
customized on a per -participant basis. Total daily insulin dose will be reduced by approximately 724 
20% as a general rule, with a recommended method outlined in a separate procedures’ manual. 725 
Further adjustments to tota l daily dose (TDD) and intraday basal rate profile may be made during 726 
the initial 2 -week use period . 727 
Participants and parent(s) will complete training on the study pump as described above, with  728 
additional emphasis on topics relevant to new pump users, suc h as infusion site initiation, 729 
cartridge/priming procedures, setting up the pump, charging the pump, navigation 730 
through menus, bolus procedures including stopping a bolus, etc. 731 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 37 OF 84 
 The study team will assist the participant/parent  in study pump infusion site i nitiation and will start 732 
the participant on the study pump. The study pump will be programmed with the participant’s 733 
insulin requirements. 734 
 
 735 
The participant/parent  will be instructed to use the system in closed -loop mode except if insul in is 736 
delivered by any means other than the study pump (e.g. injection of subcutaneous insulin via 737 
syringe in the event of infusion site failure). If insulin is delivered by any means other than the 738 
study pump, the parent  will be instructed to turn off Control -IQ for approximately four hours. 739 
The parent  will also be instructed to contact study staff if the participating child has illness with 740 
an elevated temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), other periods of 741 
significant illness, or d uring periods of use of medications such as epinephrine for the emergency 742 
treatment of a severe allergic reaction or asthma attack in addition to use of oral or injectable 743 
glucocorticoids to determine if closed-loop use should be temporarily discontinued. 744 
Parents  will be provided with sufficient supplies to last until the subsequent visit. 745 
Parents  will be provided with contact information and will be asked to call the study clinical staff 746 
for any health -related  issues and for technical issues with the syste m. Participants  may use the 747 
study pump without Control -IQ activated and study CGM  during periods of component 748 
disconnections or technical difficulties.  Parents  will also  receive study staff contact information 749 
to ask any questions they may have during the study. 750 
Study staff will discuss with the parent  that routine contact is required and will make arrangements 751 
with the parent  for the contacts.  If the parent cannot be reached, the participant’s other contact 752 
methods will be utilized, including the emergency contact.  Parents  who are not compliant with 753 
the arranged contacts on two separate occasions may be  discontinued at the discretion of the 754 
investigator.  755 
Upon completion of the CGM or study pump training components , as applicable, study staff will 756 
document, using a checklist, that the parent  is familiar with the function s/features/tasks addressed 757 
during the training. 758 
Parents  will be provided Hypoglycemia, Hyperglycemia and Ketone Guidelines ( section 8.2) for 759 
when their glucose levels are >300 mg/dL for more than 90 minutes  or >400 mg/dL at any time or 760 
<70 mg/dL or ketones ≥ 1.0 mmol/L.  761 
 
 762 
After training on the study system has been completed, participants will proceed with home use 763 
(meaning free-living use at school, home, etc.) of the study pump. 764 
Parents  may use available manufa cturer -provided software and features of the study CGM related 765 
to mobile data access or remote monitoring, but will be instructed not to use any third-party 766 
components for this purpose. 767 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 38 OF 84 
 
 
 768 
Parents  will be instructed to download the study CGM and pump and ketone meter prior to each 769 
phone or videoconference contact or on at least an every 4-week  basis throughout the remainder 770 
of the study. 771 
 
 772 
For participants who were on MDI at the time of enrollment, study staff will perform a phone call 773 
or videoconference with the parent within 3 (± 2) days  following initiation of study pump use. 774 
The following will occur: 775 
• Assessment of compliance with study device use by review of any available device data 776 
• Assessment of adverse events, adverse device effects, and device issues  777 
• Study staff will answer any questions related to device use and follow the procedure for 778 
insulin pump optimization described above using the study CGM available data from the 779 
previous two weeks.  780 
 
 781 
Study staff will perform a phone call /videoconference with the parent  within 7 (±2) days  following 782 
randomization. 783 
The following will occur: 784 
• Assessment of compliance with study device use by review of any available device da ta 785 
• Assessment of adverse events, adverse device effects, and device issues  786 
• Study staff will answer any questions related to device use and follow the procedure for 787 
insulin pump optimization described above using the study CGM available data from the 788 
previous two weeks. 789 
 
 790 
Participants will have a follow-up visit 14 (±4) days from the date of randomization. 791 
The parent  will be offered review training to address any questions on the use of the study device 792 
including meal bolus strategies and strategies related to pump use and exercise. 793 
The following will occur: 794 
• Assessment of compliance with study device use by review of any available device data  795 
• Assessment of adverse events, adverse device effects, and device issues  796 
• Study staff will answer any questions related to device use and follow the procedure for 797 
insulin pump optimization described above using the study CGM available data from the 798 
previous two weeks. 799 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 39 OF 84 
 • At in -clinic visits, the blood glucose meter and study ketone meter will be downloaded and 800 
QC tested with control solution. 801 
 Procedures for the S C Group  802 
Participants in the S C group will continue to use their existing in sulin therapy (personal pump or 803 
MDI) for the treatment of their diabetes, in conjunction with use of  the study CGM, study blood 804 
glucose meter, and study ketone meter. 805 
If a participant is using a pump with a n LGS /PLGS  feature, he/she will be allowed to cont inue 806 
using this feature during the trial. 807 
Parents  may use available manufacturer -provided software and features of the study CGM related 808 
to mobile data access or remote monitoring, but will be instructed not to use any third-party 809 
components for this purpose . 810 
 
 811 
Parents  will be instructed to upload /email data from the study CGM and study ketone m eter using 812 
commercially available software prior to each phone or videoconference contact below for 813 
clinician review.  Parents  will be provided with any software and hardware needed to perform 814 
these data uploads. 815 
 
 816 
Study staff will perform a phone call /videoconference with the participant 7(+2) days  following 817 
randomization. 818 
The following will occur: 819 
• Assessment of compliance with study device use by review of any available device data 820 
• Assessment of adverse events, adverse device effects, and device issues  821 
• Study staff will answer any questions related to device use 822 
 
 823 
Participants will have a follow-up visit 14 (±4) days from the date of randomization. 824 
The parent  will be offered review training on the use of S C during the remainder of the study, 825 
including meal bolus strategies and strategies r elated to exercise.  826 
The following will occur: 827 
• Assessment of compliance with study device use by review of any available device data 828 
• Assessment of adverse events, adverse device effects, and device issues  829 
• Study staff will review uploaded CGM data, answer any questions related to device use, 830 
and provide any recommendations for insulin therapy adjustment. 831 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 40 OF 84 
 • If visit is in -clinic, the study blood glucose meter and study ketone meter will be 832 
downloaded and QC tested . 833 
The parent  will be instructed to upload data fr om the  study CGM and ketone meter at least once 834 
every 4 weeks for the remainder of the study. 835 
 Follow- up Visits and Phone Contacts for Both Groups  836 
After the first 2 weeks, t he schedule for remaining follow -up contacts  is the same for both 837 
treatment groups. Study staff will discuss with the parent  that periodic contact is required and will 838 
make arrangements with the parent  for the contacts.  If the parent cannot be reached, the 839 
participant’s other contact methods will b e utilized, including the emergency contact. 840 
 
 841 
A follow- up in- clinic  visit will occur at  6 weeks ( ±7 days) . The following procedures  are 842 
performed in both groups, unless otherwise specified below: 843 
Assessment of compliance with study device use by revi ew of any available device data  844 
Assessment of adverse events, adverse device effects, and device issues  845 
Download of device data (study system or personal pump and study CGM, study BG meter, study 846 
ketone meter) ; in the case of videoconferences, participants  will upload or email available data 847 
prior to the visit, including CGM, pump, and ketone meter , so that clinic staff can review and 848 
download the data 849 
 
 850 
A follow- up phone call or videoconference will occur at  10 weeks ( ±7 days). At the discretion of 851 
the investigator, this  scheduled phone contact may be replaced by an in- clinic visit.  852 
The following procedures are performed in both treatment groups: 853 
• Review of available CGM , ketone meter, and/or system data to identify any safety issues 854 
associated with current insulin therapy  and diabetes management approach  855 
• Assessment of adverse events, adverse device effects, and device issues  856 
Additional phone contacts may be performed as needed. 857 
 
 858 
If needed for safety reasons at the criteria of the physician at each clinical center, optimization may 859 
be done via phone contacts , videoconferences, or in -clinic visits.  860 
Data will be obtained from CGM and/or pump downloads during the contact . Adjustments to pump 861 
settings (basal rates, correction factor, insulin- to-carbohydrate ratio, etc.) or injection strategies 862 
will be made in response to major trends observed in the CGM data, with flexibility for clinicians 863 
to adhere to guidelines and practices established at each individual practice rather than a fixed set 864 
of heuristics for all clinical centers . 865 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 41 OF 84 
 
 
 866 
All participants will have a 13- Week (±7 days) visit during which the following will occur: 867 
• Collection of a blood sample to send to the central laboratory for HbA1c determination. 868 
• Completion of questionnaires  869 
• Weight and height measurement s will be repeated 870 
• Assessment of adverse events, adverse device effects, and device issues  871 
• Download of device data (study system or  personal pump and study CGM, study BG meter, 872 
study ketone meter) as available  873 
 Early Termination Visit (If Applicable)  874 
Participants will be asked to come for an end of study visit in the event of withdrawal or early 875 
termination.  876 
 Unscheduled Visits  877 
Particip ants may have unscheduled visits during the study period if required for additional device 878 
training or other unanticipated needs per the study investigator discretion. 879 
  880 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 42 OF 84 
 Chapter 6:  Extension Phase  Procedures   881 
At the conclusion of the 13- week RCT , all participants wi ll use the Control- IQ closed -loop 882 
system  during a 13-week Extension Phase.  883 
An updated version of the Control-IQ system with enhanced usability will be used  during the 884 
Extension Phase. Participants assigned to the SC group during the RCT period will receive 885 
training based on the updated pump as described below. Participants assigned to the CLC group 886 
will receive a brief training session to review any new or changed features of the pump.  887 
Initiation of the updated Control-IQ pump may be deferred by up to 2 weeks if needed, with the 888 
participant continuing on the treatment used during the RCT period during this time and the 889 
overall duration of the Extension Phase increasing by up to 2 weeks.  890 
 Visit and Contact Schedule  891 
During the Extension period, visits and contacts will be scheduled as outlined in Table 4 below: 892 
Table 4: Extension Phase Visit and Phone Contact Schedule  893 
Target Day/Week1 Contact Typ e2 Target/ Allowable Window  
(around Target Day/Week)  
13 weeks + 3 days  VC/P  ± 2 days  
14 weeks  P ± 2 days  
15 weeks  VC/V ± 4 days  
19 weeks  VC/V ± 7 days  
23 weeks  P ± 7 days  
26 weeks  VC/V ± 7 days  
1 The “13 weeks” and subsequent visit targets reflect a participant who had no delay between the 13 -week visit of the RCT and 894 
initiation of use of the updated Control -IQ pump . Targets and associated windows may be shifted by up to 2 weeks for 895 
participants whose initiation is delayed .  896 
2 Contact Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by 897 
Videoconferences or Clinic Visits and Videoconferences may be replaced by Clinic Visits at investigator discretion  898 
 899 
 Study Pump Initiation  900 
Participants assigned to the SC group during the initial 13- Week RCT period will initiate use of 901 
the updated study pump either the same day as the 13 -Week visit or within 2 weeks of this visit. 902 
The procedures described in section 5.3 above will be followed to initiate these participants on 903 
the study pump.   904 
Participants assigned to the CLC group during the RCT period will switch to the updated version 905 
of the Control- IQ system and will r eceive training on its  new features.  This will occur either the 906 
same day as the 13 -Week visit or within 2 weeks of this visit.  907 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 43 OF 84 
 
 Visits, Videoconferences, and Phone Calls for All Participants  908 
 
 909 
Study staff will perform a phone call or videoconference with the parent within 3  (±2) days  910 
following initiation of Extension Phase study pump use. Procedures will mirror those described in 911 
section 5.3.6 above. 912 
 
 913 
Participants will have a phone call or videoconference at 14 Weeks ( ±2 days) . Procedures will 914 
mirror those described in section 5.3.7 above. 915 
 
 916 
Participants will have a follow -up visit at 15 Weeks ( ±4 days). Procedures will mirror those 917 
descri bed in section 5.3.8 above. 918 
 
 919 
A follow-up in- clinic visit will occur at 19 weeks ( ±7 days). Procedures will mirror those 920 
described in section 5.5.1 above. 921 
 
 922 
A follow-up phone call will occur at 23 weeks (±7 days). Procedures will mirror those described 923 
in section 5.5.2 above. 924 
 
 925 
A follow-up in -clinic visit will occur at 2 6 weeks ( ±7 days). Procedures will mirror those 926 
described in section 5.5.4 above. 927 
Participants will have the opportunity to participate in Focus Group sessions as described in 928 
section 9.3 below. 929 
Participants will be given the option to continue use of the Control- IQ closed -loop system during 930 
an additional Extended Use period as described in the next chapter. Participants who do not wish 931 
to continue to the Extended Use period will be switched back to the insulin pump or MDI 932 
therapy that was in use prior to the study. 933 
 
 934 
If needed for safety reasons at the criteria of the physician at each clinical center, optimization 935 
may be done via phone contacts, videoconferences, or in- clinic visits as described in  section 936 
5.5.3 above. 937 
 Unscheduled Visits  938 
Participants may have unscheduled visits during the study period if required for additional device 939 
training or other unanticipated needs per the study investigator discretion. 940 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 44 OF 84 
 
 Participant Acc ess to Study Device at Study Closure  941 
Participant s not continuing to the Extended Use period will return all investigational study devices 942 
and supplies (insulin pump, CGM and related supplies).  Participant s may keep the study ketone 943 
meter and study glucometer if these devices are not marked for investigational use only. 944 
  945 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 45 OF 84 
 Chapter 7:  Extended Use Period Procedures   946 
At the 26-W eek Visit of the Extension Phase, participants will be given the option to continue 947 
use of the Control- IQ closed -loop system during an additional Extended Use period. Participants 948 
who completed the 26- Week Visit before the addition of this Extended Use period to the study 949 
protocol will be eligible to rejoin the study and participate as long as they completed their 26- 950 
Week Visit within the  prior 4 months. 951 
The same version of the Control- IQ system in use during the 13-Week Extension Phase will be 952 
used during the Extended Use period. 953 
Informed Consent will be obtained from eligible participants who are interested in participating 954 
in the Extended Use period. The informed consent process will mirror the process described 955 
above in section 2.1.1. 956 
 Visit and Contact Schedule  957 
During the Extended Use period, visits and contacts will be scheduled as outlined in Table 5 958 
below: 959 
Table 5: Extended Use Period  Visit and Phone Contact Schedule  960 
Target Day/Week with 
respect to initiation  of 
Extended Use period  Contact Type1 Target/ Allowable Window  
(around Target Day/Week)  
0 days (Retraining) 2 VC/V N/A 
3 days2 VC/P ± 2 days  
1 week2 VC/P  ± 2 days 
13 weeks  VC/V ± 7 days  
26 weeks  VC/V ± 7 days  
Final Visit  VC/V N/A 
1 Contact Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by 961 
Videoconferences or Clinic Visits and Videoconferences may be replaced by Clinic Visits at investigator discretion  962 
2 Only for participants who had a ga p between the 26 -Week Visit and the initiation of the Extended Use period during  which they 963 
stopped use of the study pump and reverted to MDI or personal pump insulin therapy  964 
 Visits, Videoconferences, and Phone Calls for Participants Re- Initiating Study Pump 965 
Use After a Gap in Use 966 
 
 967 
Participants who had a gap between the 26-Week Visit and the initiation of the Extended Use 968 
period during which they reverted to MDI or personal pump insulin therapy will have a visit to 969 
receive retrain ing on the study pump prior to re-initiation of study pump use. 970 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 46 OF 84 
 The procedures described in section 5.3 above will be followed to re -initiate these participants on 971 
the study pump.   972 
 
 973 
Study staff will perform a phone call or videoconference with the parent within 3  (±2) days  974 
following re-initiation of study pump use. Procedures will mirror those described in section 5.3.6 975 
above. 976 
 
 977 
Participants will have a phone call or videoconference within 7 days (±2 days) following re- 978 
initiation of study pump use. Procedures will mirror those described in section 5.3.7 above. 979 
 Visits, Videoconferences, and Phone Calls for All Participants  980 
 
 981 
A follow -up in- clinic visit will occur 13 weeks ( ±7 days) after the start of the Extended Use period. 982 
The following procedures will be  performed in both groups: 983 
• Collection of a blood sample to send to the central laboratory for HbA1c determination  984 
• Assessment of compliance with study device use by review of any available device data 985 
• Assessment of adverse events, adverse device effects, and device issues  986 
• Download of device data (study system or personal pump and study CGM, study BG meter, 987 
study ketone meter); in the case of videoconferences, participants will upload or email 988 
available data prior to the visit, including CGM, pump, and ketone meter, so that clinic 989 
staff can review and download the data  990 
Every 13 weeks ( ±7 days) thereafter, another follow -up clinic visit will occur involving the same 991 
procedures described above. 992 
 
 993 
A final follow-up in- clinic  or videoconference visit will occur no later than July 31, 2022. 994 
Procedures will mirr or those described in section 7.3.1 above, except that no blood sample will 995 
be collected . 996 
Participants will be switched back to the insulin pump or MDI therapy that was in use prior to 997 
the study. 998 
 
 999 
If needed for safety reasons at the criteria of the physician at each clinical center, optimization 1000 
may be done via phone contacts, videoconferences, or in- clinic visits as described in section 1001 
5.5.3 above. 1002 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 47 OF 84 
 
 Unscheduled Visits  1003 
Participants may have unscheduled visits during the study period if required for additional device 1004 
training or other unanticipated needs per the study investigator discretion. 1005 
 Participant Access to St udy Device at Study Closure  1006 
Participant will return all investigational study devices and supplies (insulin pump, CGM and 1007 
related supplies) at study closure.  Participant may keep the study ketone meter and study 1008 
glucometer if these devices are not marked for investigational use only. 1009 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 48 OF 84 
 Chapter 8:  Study Devices  1010 
 Description of the Investigational Device 1011 
 
 1012 
The study system will include the Tandem t:slim X2 with Control-IQ technology. 1013 
 
 1014 
The study CGM will include Dexcom G6 transmitter and sensors.  T he CGM sensor will be 1015 
replaced at least once every 10 days.  1016 
 
 1017 
Blood glucose levels will be measured using the study’s  blood glucose meter (glucometer) and the 1018 
CGM device will be calibrated if needed using the study glucometer and strips in accordance with 1019 
the manufacturer’s labeling.  1020 
 
 1021 
Blood ketone levels will be measured using the Abbott Precision Xtra meter and strips in 1022 
accordance with the m anufacturer’s labeling.  The blood glucose meter component of the Precision 1023 
Xtra device will not be used. 1024 
 
 1025 
Device accountability procedures will be detailed in the clinical center  procedures manual. 1026 
 
 1027 
Participants to perform QC testing at home per manufacturer guidelines. 1028 
All study blood ketone meters will be QC tested with control solution if available during all office 1029 
visits.  A tested meter will not be used in a study if it does not read within th e target range at each 1030 
concentration per manufacturer labeling.  The participant will be instructed to contact study staff 1031 
for a replacement of the meter, test strips, and control solution if a meter fails QC testing at home.  1032 
Participants will be instructe d on how to perform blood ketone testing. 1033 
Participants will be given guidelines for treatment of elevated blood ketones. 1034 
 Safety Measures  1035 
 
 1036 
Throughout the study, participants will be instructed to calibrate the study CGM in accordance 1037 
with man ufacturer labelling.  1038 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 49 OF 84 
 
 
 1039 
If the CGM signal becomes unavailable for more than 20 minutes consecutively, Control -IQ or 1040 
closed loop will not operate to automatically adjust insulin. If the CGM is not connected, the 1041 
system will revert to usual function of the pump and deliver insulin with the insulin dosing 1042 
parameters programmed in the system for that individual. Resumption of Closed- Loop will 1043 
occur  automatically once CGM signal is available again.  1044 
If the study system is unable to activate Control -IQ for any reason, the pump will automatically 1045 
revert to preprogrammed basal insulin delivery without any need for instruction from the user. 1046 
If the pump detects a system error that does not allow it to operate, the Malfunction Alarm will 1047 
display and the participant will be instructed to contact Tandem Technical Support via the study 1048 
team.  1049 
 
 1050 
During the course of the study, participants will be permitted to change the CGM low glucose 1051 
threshold alert setting  on their device or mobile app, but will be instructed to choose a value no 1052 
less than 70 mg/dL. 1053 
The t:slim X2 with Control- IQ system will issue a  predictive hypoglycemia alert (Control- IQ Low 1054 
Alert) when the system predicts BG <70 mg/dL within the next 15 minutes (<80 mg/dL when 1055 
exercise mode is activated ). 1056 
If the participant receives a Control- IQ Low Alert , a message appears on the user interface ( UI) 1057 
that is accompanied by vibration followed by vibrations and/or sound if not acknowledged by the 1058 
user in 5 minutes.  This alert remains on the screen until acknowledged by the user. The user is 1059 
prompted to test blood sugar and treat with carbs. 1060 
 
 1061 
During the course of the study, participants will be permitted to change the CGM high glucose 1062 
threshold alert setting  on their device or mobile app, but will be instructed to choose a value no 1063 
greater than 300 mg/dL. 1064 
The t:slim X2 with Control- IQ system wi ll issue a predictive hyperglycemia alert (Control -IQ 1065 
High Alert) when the system has increased insulin delivery, but detects a CGM value above 200 1066 
mg/dL and does not predict the value will decrease in the next 30 minutes. 1067 
If the participant receives a Control -IQ High Alert , a message appears on the UI that is 1068 
accompanied by vibration followed by vibrations and/or sound if not acknowledged by the user in 1069 
5 minutes. This alert remains on the screen until acknowledged by the user. The user is prompted 1070 
to check the site for occlusion and test blood glucose. 1071 
If a participant’s CGM reading is >300 mg/dL for over 90 minutes  or ≥400 mg/dL at any point, or 1072 
if CGM reading is >250 mg/dL more than 3 hours after a meal, the participant  took correction 1073 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 50 OF 84 
 insulin, and CGM didn’t decrease by at least 50 mg/dL , the participant will be instructed to take 1074 
the following steps: 1075 
Inspect infusion site for problems 1076 
Perform a blood glucose meter check. 1077 
If the blood glucose is >300 mg/dL, check for blood ketones with the study ket one meter.  1078 
If the ketone level is ≥1.0 mmol/L, take correction insulin, change insulin (pump) infusion site and 1079 
contact study staff. 1080 
If a participant administers correction insulin via insulin syringe, participants will be instructed to 1081 
turn Control- IQ off for approximately four hours. 1082 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 51 OF 84 
 Chapter 9:  Testing Procedures , Questionnaires , and Focus Groups  1083 
 Laboratory Testing 1084 
 
 1085 
Performed at the Randomization visit, 13-W eek visit, and 26- Week visit  1086 
Blood samples will be sent to the central laboratory for sample analysis using an NGSP approved 1087 
method. 1088 
 Questionnaires  1089 
The q uestionnaires listed  below are completed by participant s’ parents at Screening , 13 w eeks, 1090 
and 26 weeks  for all participants  except as noted .  The questionnaires  will be family and age 1091 
appropriate and are described briefly below.  The procedures for administration are described in 1092 
the clinical center procedures manual. 1093 
Pediatric Quality of Life – Parent  1094 
Pediatric Inventory for Parents  1095 
INSPIRE Survey – Parent  1096 
Pittsburgh Sleep Quality Index (PSQI) – Parent  1097 
Fear of Hypoglycemia Survey- Parents  (HFS -P) 1098 
Hypoglycemia Confidence Scale (HCS)  1099 
System Usability Scale (SUS) (Closed -Loop participants only at 13 and 26 weeks) 1100 
Administration time is approximately 35 minutes.  1101 
 
 1102 
This is a 3 2-item scale developed and validated for the measurement of diabetes -specific quality 1103 
of life. Participants record the extent to which their child experienced each of 32 problems 1104 
related to diabetes in the prior month.  1105 
Administration time is approximately 5 minutes.  1106 
 
 1107 
This is a widely -used, 42-item measure of parenting stress designed for parents of youth with 1108 
type 1 diabetes.  1109 
Administration time is approximately 6 minutes.  1110 
 
 1111 
The INSPIRE ( Insulin Delivery S ystems: Perceptions, I deas, Reflections and E xpectations) survey 1112 
was developed to assess various aspects of a user’s experience regarding automated insu lin 1113 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 52 OF 84 
 delivery for both patients and family members. The surveys include various topics important to 1114 
patients with type 1 diabetes and their family members based upon >200 hours of  qualitative 1115 
interviews and focus groups. T he parent pre -assessment survey and parent post -assessment survey 1116 
both contain 19 items. Response options for all surveys include a 5- point Likert scale from strongly 1117 
agree to strongly disagree, along with an N/A option. 1118 
Administration time is approximately 5 minutes.  1119 
 
 1120 
An abbreviated 9-question version of the Pittsburgh Sleep Quality Index (PSQI ), a validated tool 1121 
for assessing self -reported sleep quantity and quality, will be completed by parents. S even 1122 
component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The 1123 
component scores are summed to produce a global score (range 0 to 21). Higher scores indicate 1124 
worse sleep quality.  1125 
Administration time is approximately 3 minutes.  1126 
 
 1127 
The Hypoglycemia Fear Survey- Parent  is a validated tool of 25 items to assess parents’ anxiety 1128 
and behavior concerning possible hypoglycemia . Items are rated on a 5 -point Likert scale 1129 
(0=never, 4=always), with higher scores indicating higher fear of hypoglycemia.  1130 
Administration time is approximately 4 minutes.  1131 
 
 1132 
The scale comprises 8 items and measures confidence hypoglycemia can be treated or prevented 1133 
in various situations.  1134 
Administration time is approximately 3 minutes.  1135 
 
 1136 
The System Usability Scale (SUS) is a 10 -item questionnaire that measures the overall usability 1137 
of a system. It is a valid and reliable measure of the perceived usability of a sys tem and is 1138 
technology- agnostic. The questionnaire presents statements with five response options (anchoring 1139 
the options from strongly disagree to strongly agree) and asks users to rate their agreement to the 1140 
statements.  User scores are transformed into a composite score, from 0 to 100, and this score is 1141 
taken as an overall measure of the system’s usability; higher scores indicate better perceived 1142 
usability.  1143 
Administration time is approximately 5 minutes . 1144 
 1145 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 53 OF 84 
 
 Focus Groups  1146 
Focus groups will be completed following the 26-Week Visit . The focus groups will be conducted 1147 
virtually using HIPAA-approved software. 1148 
Focus groups will include 3- 5 individuals and a script of open- ended questions to gather feedback 1149 
and reactions to the closed loop system, the clinical trial,  and QoL changes. There will also be time 1150 
for discussion of content raised by parents. If parents are able to have the child participant attend 1151 
briefly to answer a few questions, this will be attempted.  1152 
Sessions will be audio- and video- taped and transcribed by a professional transcription service. 1153 
Otherwise, these recordings will not be shared for any non- study purposes. Transcriptions will use 1154 
a code for participants, such as “Participant 1”, and will not contain names or other identifiers of 1155 
participants.   1156 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 54 OF 84 
 Chapter 10:  Unanticipated Problem, Adverse Event, and Device Issues  1157 
Reporting 1158 
 Unanticipated Problems  1159 
Site investigators will promptly report to the Coordinating Center on an eCRF all unanticipated 1160 
problems meeting the criteria below. Problems meeting IRB reporting requirements will be 1161 
reported to the IRB within 7 calendar days of the site becoming aware of the problem. For this 1162 
protocol, an unanticipated problem is an incident, experience, or outcome that meets all of the 1163 
following criteria:  1164 
• Unexpected (in  terms of nature, severity, or frequency) given (a) the research procedures 1165 
that are described in the protocol related documents, such as the IRB- approved research 1166 
protocol and informed consent document; and (b) the characteristics of the subject 1167 
population being studied 1168 
• Related or possibly related to participation in the research (possibly related means there is 1169 
a reasonable possibility that the incident, experience, or outcome may have been caused 1170 
by the procedures involved in the research)  1171 
• Suggests that the research places participants or others at a greater risk of harm than was 1172 
previously known or recognized ( including physical, psychological, economic, or social 1173 
harm)  1174 
The Coordinating Center also will report to the IRB all unanticipated problems not di rectly 1175 
involving a specific site such as unanticipated problems that occur at the Coordinating Center or 1176 
at another participating entity such as a pharmacy or laboratory. These instances must be 1177 
reported to the JCHR IRB within seven calendar days of recognition. The Director of the Human 1178 
Research Protection Program will report to the appropriate regulatory authorities if the IRB 1179 
determines that the event indeed meets the criteria of an Unanticipated Problem requiring 1180 
additional repor ting. 1181 
 Adverse Events  1182 
 
 1183 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 1184 
relationship between the adverse event and the device(s) under investigation. 1185 
Serious Adverse Event (SAE): Any untoward medical occurrence that: 1186 
Results in death. 1187 
Is life -threatening; (a non -life-threatening event which, had it been more severe, might have 1188 
become life -threatening, is not necessarily considered a serious adverse event). 1189 
Requires inpatient hospitalization or prolongation of existing hos pitalization.  1190 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 55 OF 84 
 Results in persistent or significant disability/incapacity or substantial disruption of the ability to 1191 
conduct normal life functions (sight threatening). 1192 
Is a congenital anomaly or birth defect. 1193 
Is considered a significant medical event by the investigator based on medical judgment (e.g., may 1194 
jeopardize the participant or may require medical/surgical intervention to prevent one of the 1195 
outcomes listed above). 1196 
Unanticipated Adverse Device Effect (UADE):  Any serious adverse effect on health or safety or 1197 
any life -threatening problem or death caused by, or associated with, a device, if that effect, 1198 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 1199 
investigational plan or application (including a supplementary plan or application), or any other 1200 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 1201 
of participants (21 CFR 812.3(s)). 1202 
Adverse Device Effect (ADE):  Any untoward medical occurrence in a study par ticipant which the 1203 
device may have caused or to which the device may have contributed (Note that an Adverse Event 1204 
Form is to be completed in addition to a Device Deficiency or Issue Form, unless excluded from 1205 
reporting as defined in section 10.3).  An event that occurs solely due to participant (i.e., user) 1206 
error in which the device functions properly generally will not be considered an ADE unless it is 1207 
determined that the instructions on the screen of the device or user manual (or similar training 1208 
materials) may have contributed to the event (note: the event may still meet criteria for reporting 1209 
as an adverse e vent). 1210 
Device Complaints and Malfunctions:  A device complication or complaint is something that 1211 
happens to a de vice or related to device performance, whereas an adverse event happens to a 1212 
participant.  A device complaint may occur independently from an AE, or along with an AE.  1213 
An AE may occur without a device complaint or there may be an AE related to a device com plaint.  1214 
A device malfunction is any failure of a device to meet its performance specifications or otherwise 1215 
perform as intended.  Performance specifications include all claims made in the labeling for the 1216 
device.  The intended performance of a device refers to the intended use for which the device is 1217 
labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites  will not be asked to 1218 
distinguish between device complaints and malfunctions. 1219 
 
 1220 
For this protocol, a reportable adverse event includes any untoward medical occurrence that meets 1221 
one of the following criteria: 1222 
1. An SAE or an AE associated with a visit to a hospital emergency department 1223 
2. An ADE  as defined in section 10.2.1, unless excluded from reporting in section 10.3 1224 
3. An AE as defined in section 10.2.1 occurring in association with a study procedure 1225 
4. An AE as defined in section 10.2.1 not related to a device issue which leads to temporary or 1226 
permanent discontinuation of a study device 1227 
5. An AE as defined in section 10.2.1 that affects the participant’s ability to complete any study 1228 
procedures 1229 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 56 OF 84 
 6. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  1230 
7. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a hyperglycemic or 1231 
ketosis event meeting the criteria defined below  1232 
Hypoglycemia and hyperglycemia not meeti ng the criteria below will not be recorded as adverse 1233 
events unless associated with an Adverse Device Effect.  Skin reactions from sensor placement are 1234 
only reportable if severe and/or required treatment. 1235 
All reportable AEs —whether volunteered by the participant, discovered by study personnel during 1236 
questioning, or detected through physical examination, laboratory test, or other means —will be 1237 
reported on an AE form online.  Each AE form is reviewed by the Medical Monitor to assess safety 1238 
and to verify the coding and the reporting that is required. 1239 
 
 1240 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an adverse event 1241 
when the following definition for severe hypoglycemia is met:  the event required assistance of 1242 
another person due to altered consciousness, and required another person to actively administer 1243 
carbohydrate, glucagon, or other resuscitative actions.  This means that the participant was 1244 
impaired cognitively to the point that he/she was unable to treat hi mself/herself, was unable to 1245 
verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure or 1246 
loss of consciousness.  These episodes may be associated with sufficient neuroglycopenia to 1247 
induce seizure or loss of consciousness.  If plasma glucose measurements are not available during 1248 
such an event, neurological recovery attributable to the restoration of plasma glucose to normal is 1249 
considered sufficient evidence that the event was induced by a low plasma glucose concentration. 1250 
When a hypoglycemic event meets the above reporting requirements, a Hypoglycemia Form 1251 
should be completed in addition to the Adverse Event Form. Severe hypoglycemia events should 1252 
be considered to be serious adverse events with respect to reporting requi rements . 1253 
 
 1254 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 1255 
event when one of the following criteria is met:  1256 
the event involved DKA, as defined by the Diabetes Control and Complications  Trial (DCCT) and 1257 
described below  1258 
evaluation or treatment was obtained at a health care provider facility for an acute event involving 1259 
hyperglycemia or ketosis , or the participant contacted the site and received guidance on how to 1260 
manage the hyperglycemia/ ketosis 1261 
blood ketone level ≥ 1.0 mmol/L, even if there was no communication with a health care provider 1262 
at the time of the event  1263 
Hyperglycemic events are classified as DKA if the following are present:  1264 
Symptoms such as polyuria, polydipsia, nausea, or vomiting; 1265 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 57 OF 84 
 Serum ketones ≥ 1.5 mmol/L or large/moderate urine ketones; 1266 
Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO 2) <15; and 1267 
Treatment provided in a health care facility  1268 
When a hyperglycemia/ketotic qualifies as an SAE as defined in section 10.2.1, a 1269 
Hyperglycemia/DKA Form should be completed in addition to the Adverse Event Form. Events 1270 
meeting DKA criteria should be considered to be serious adverse events with respect to reporting 1271 
requirements. Hyperglycemia events not meeting criteria for DKA generally will not be considered 1272 
as serious adverse events unless one of the SAE criteria in section 10.2.1 is met.  1273 
 
 1274 
The study investigator will assess the relationship of any adverse event to be related or unrelated 1275 
by determining if there is a reasonable possibility that the adverse event may have been caused by 1276 
the study device. 1277 
To ensure consistency of adverse event causality assessments, investigators should apply the 1278 
following general guideline when determining whether an adverse event is related: 1279 
Yes 1280 
There is a plausible temporal relationship b etween the onset of the adverse event and the study 1281 
intervention, and the adverse event cannot be readily explained by the participant’s clinical state, 1282 
intercurrent illness, or concomitant therapies; and/or the adverse event follows a known pattern of 1283 
response to the study intervention; and/or the adverse event abates or resolves upon discontinuation 1284 
of the study intervention or dose reduction and, if applicable, reappears upon re- challenge.  1285 
No 1286 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 1287 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 1288 
medication); and/or the adverse event has no plausible temporal relationship to study intervention.  1289 
 
 1290 
The severity (intensity) of an adverse event will be rated on a three point scale: (1) mild, (2) 1291 
moderate, or (3) severe.  A severity assessment is a clinical determination of the intensity of an 1292 
event. Thus, a severe adverse event is not necessarily serious.  For example, itching for several 1293 
days may be rated as severe, but may not be clinically serious. 1294 
• MILD: Usually transient, requires no special treatment, and does not interfere with the 1295 
participant’s daily activities.  1296 
• MODERATE: Usually causes a lo w level of inconvenience, discomfort or concern to the 1297 
participant and may interfere with daily activities, but is usually ameliorated by simple 1298 
therapeutic measures and participant is able to continue in study. 1299 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 58 OF 84 
 • SEVERE: Interrupts a participant’s usual dai ly activities, causes severe discomfort, may 1300 
cause discontinuation of study device, and generally requires systemic drug therapy or 1301 
other treatment.  1302 
 
 1303 
For a serious adverse event that is considered possibly related to study device, the Medical 1304 
Monitor will classify the event as unexpected if the nature, severity, or frequency of the event is 1305 
not consistent with known risk information. 1306 
 
 1307 
Adverse events will be coded using the MedDRA dictionary. To facilitate coding, the site  will 1308 
enter a preliminary MedDRA code which the Medical Monitor may accept or change (the Medical 1309 
Monitor’s MedDRA coding will be used for all reporting). The Medical Monitor will review the 1310 
investigator’s assessment of causality and may agree or disagree.   Both the investigator’s and 1311 
Medical Monitor’s assessments will be recorded.  The Medical Monitor will have the final say in 1312 
determining the causality as well as whether an event is classified as a serious adverse event and/or 1313 
an unanticipated adverse device effect . 1314 
 
 1315 
The outcome of each reportable adverse event will be classified by the investigator as follows: 1316 
RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  1317 
Record the AE/SAE stop date.  1318 
RECOVERED/R ESOLVED WITH SEQUELAE – The event persisted and had stabilized without 1319 
change in the event anticipated.  Record the AE/SAE stop date. 1320 
FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that was 1321 
the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the time of death; 1322 
however, were not the cause of death, will be recorded as “resolved” at the time of death.  1323 
NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 1324 
event was ongoing with an undetermined outcome. 1325 
o An ongoing outcome will require follow -up by the site  in order to determine the final 1326 
outcome of the AE/SAE. 1327 
o The outcome of an ongoing event at the time of death that was not the cause of death, 1328 
will be updated and recorded as “resolved” with the date of death recorded as the stop 1329 
date.  1330 
UNKNOWN – An unknown outcome is defined as an inability to access the participant or the 1331 
participant’s records to determine the outcome (for example, a participant that was lost to follow - 1332 
up). 1333 
If any reported adverse events are ongoing when a participant completes the study (or withdraws), 1334 
adverse events classified as UADEs will be followed until they are either resolved, or have no 1335 
prospect of improvement or change, even after the par ticipant has completed all applicable study 1336 
visits/contacts. For all other adverse events, data collection will end at the time the participant 1337 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 59 OF 84 
 completes the study. Note: participants should continue to receive appropriate medical care for an 1338 
adverse event  after their participation in the study ends. 1339 
 Reportable Device Issues  1340 
All UADEs and ADEs as defined in section 10.2.1  will be reported on both a device issue form 1341 
and AE form, except for skin reactions from CGM sensor placement or pump infusion set 1342 
placement that do not require pharmacologic treatment.  As noted in section 10.2.1, events that 1343 
occur due to participant (user) error generally will not require completion of a device issue form. 1344 
Such ‘errors’ could include improper use of an insulin pump or using a pump infusion set or 1345 
CGM sensor for a period of time longer than its labeling. 1346 
Device complaints and device malfunctions will be reported except in the following 1347 
circumstances. These occurrences are expected and w ill not be reported on a Device Issue Form 1348 
assuming criteria for a UADE or ADE have not been met:  1349 
CGM sensor lasting fewer days than expected per manufacturer  1350 
CGM tape adherence issues  1351 
Battery lifespan deficiency due to inadequate charging or extensive wir eless communication  1352 
Intermittent device component disconnections/communication failures not requiring system 1353 
replacement or workaround/resolution not specified in user guide/manual. 1354 
Device issues clearly addressed in the user guide manual that do not require additional 1355 
troubleshooting 1356 
 Timing of Event Reporting 1357 
SAEs possibly related to a study device or study participation and UADEs must be reported to 1358 
the Coordinating Center within 24 hours of the site becoming aware of the event.  This can occur 1359 
via phone or email, or by completion of the online serious adverse event form and device issue 1360 
form if applicable. If the form is not initially completed, it should be competed as soon as 1361 
possible after there is sufficient information to evaluate the event. All othe r reportable ADEs and 1362 
other reportable AEs should be submitted by completion on the online form within 7 days of the 1363 
site becoming aware of the event.  1364 
The Coordinating Center will notify all participating investigators of any adverse event that is 1365 
serious, related, and unexpected. Notification will be made within 10 working days after the 1366 
Coordinating Center becomes aware of the event. 1367 
Each principal investigator is responsible for reporting serious study- related adverse events and 1368 
abiding by any other reporting requirements specific to his/her Institutional Review Board or 1369 
Ethics Committee.  Sites must report all serious, related adverse events within seven calendar 1370 
days. 1371 
Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a 1372 
UADE is confirmed, and if indicated, report the results of the investigation to all overseeing 1373 
IRBs, and the FDA within 10 working days of the Sponsor becoming aware of the UADE per 1374 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 60 OF 84 
 21CFR 812.46(b) (2).  The Medical Monitor must determine if the UADE presents an 1375 
unreasonable risk to participants.  If so, the Medical Monitor must ensure that all investigations, 1376 
or parts of investigations presenting that risk, are terminated as soon as possible but no later than 1377 
5 working days after the Medical Monitor makes this determination and no later than 15 working 1378 
days after first receipt notice of the UADE.  1379 
Device malfunctions will be handled by the Sponsor or designee as described below.  In the case 1380 
of a CGM transmitter or sensor device malfunction, informatio n will be forwarded to Dexcom by 1381 
the site personnel, to be handled by their complaint management system. 1382 
 Safety Oversight 1383 
The study Medical Monitor will review all adverse events and adverse device events that are 1384 
reported during the study.  SAEs typically will be reviewed within 24 hours of reporting.  Other 1385 
AEs typically will be reviewed on a weekly basis. Additionally, the Medical Monitor will review 1386 
compiled safety data at periodic intervals (generally timed to the review of compiled safety data 1387 
by the DSMB).  1388 
The Protocol Chair will be informed of all cases of severe hypoglycemia and DKA and the 1389 
Medical Monitor’s assessment of relationship to the study device; and informed of all reported 1390 
device issues.  1391 
A Data and Safety Monitoring Board (DSMB) will be informed of all cases of s evere 1392 
hypoglycemia and diabetic ketoacidosis irrespective of device relationship, all device- related 1393 
SAEs, and all UADEs at the time that they occur during the study and will review compiled 1394 
safety data at periodic intervals. The DSMB also will be informed  of any ADEs not meeting 1395 
criteria for a UADE if the Medical Monitor requests the DSMB review.  The DSMB can request 1396 
modifications to the study protocol or suspension or outright stoppage of the study if deemed 1397 
necessary based on the totality of safety data available. Details regarding DSMB review will be 1398 
documented in a separate DSMB document. 1399 
 Stopping Criteria  1400 
 
 1401 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1402 
event (or a malfunction that could have led to severe hypoglycemia or DKA), use of the study 1403 
pump will be suspended while the problem is diagnosed. The UADE will be reported to the IRB, 1404 
DSMB, and FDA. After assessment of the problem and any correction, use of the closed -loop 1405 
functionality  will not be restarted until approval is received from the IRB, DSMB, and FDA. 1406 
In the absence of a device malfunction, use of the study pump by a participant will be 1407 
discontinued if any of the following occur:  1408 
The investigator believes it is unsafe for the participant to continue on the intervention.  This could 1409 
be due to the development of a new medical condition or worsening of an existing condition; or 1410 
participant behavior contrary to the indications for use of the device that impos es on the 1411 
participant’s safety  1412 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 61 OF 84 
 The participant’s parent  requests that the treatment be stopped  1413 
Two distinct episodes of DKA as defined in section 10.2.4 1414 
Two distinct severe hypoglycemia events as defined in section 10.2.3 1415 
One episode of DKA as defined in section 10.2.4 and one severe hypoglycemia event as defined 1416 
in section 10.2.3 1417 
Each DKA or severe hypoglycemia event will be reviewed by the Medical Monitor and by the 1418 
DSMB with respect to determination of cause and whether the occurrence of the event can be 1419 
attributed to use of the Control- IQ closed -loop feature.  1420 
An additional requirement for continued study pump use following a single DKA or severe 1421 
hypoglycemia event will be that (1) the site investigator believes that the event is explainable, 1422 
unlikely to recur, and that it is safe for the participant to continue to use the system and (2) the 1423 
Medical Monitor and DSMB concur. If either the Medical Monitor or DSMB determines that the 1424 
occurrence of the event indicates that it is not safe for the participant to continue to use the study 1425 
pump, use will be discontinued. 1426 
Even if the study device system is discontinued, the participant will be encouraged to remain in 1427 
the study through the final study visit 1428 
 
 1429 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1430 
hyperglycemia event (as defined in section 10.2.4), use of the study pump will be suspended while 1431 
the problem is diagnosed. 1432 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1433 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1434 
study activities may resume if the underlying problem can be corrected by a protocol or system 1435 
modification that will not invalidate the results obtained pr ior to suspension.  1436 
The study Medical Monitor and DSMB will review all adverse events and adverse device events 1437 
that are reported during the study. SH and DKA event review will occur for each such event on an 1438 
expedited basis , and compiled safet y data, including SH and DKA event rates, will be reviewed at 1439 
approximately 6-month intervals.  The DSMB will be provided with age -specific DKA and SH 1440 
rates from the T1D Exchange registry for means of comparison. The Medical Monitor or DSMB 1441 
may request suspension of study activities or stoppage of the study if deemed necessary based on 1442 
the totality of safety data available. 1443 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 62 OF 84 
 Chapter 11:  Miscellaneous Considerations  1444 
 Drugs Used as Part of the Protocol 1445 
Participants will use lispro , aspart , or glusiline  rapid -acting insulin prescribed by their personal 1446 
physician. 1447 
 Collection of Medical Conditions and Medications  1448 
Pre-Existing Condition: Any medical condition that is either present at screening, a chronic 1449 
disease, or a prior condition that could impact the participant’s health during the course of the 1450 
study (e.g., prior myocardial infarction or stroke). 1451 
Medical Conditions during the study:  In addition to conditions meeting the reporting 1452 
requirements for an adverse event or device issue as described above, the following medical 1453 
conditions should also be reported: (1) new diagnosis of a chronic disease (i.e., not present at the 1454 
time of enrollment), and (2) any medical condition that could affect the participant’s ability to 1455 
carry out any aspect of the protocol or could affect an outcome assessment.  1456 
Medications: All medication for the treatment of chronic pre -existing conditions, medical 1457 
conditions (including medical conditions that do not require recording), and/or adverse events 1458 
that the participant is curr ently taking at screening and during the course of the study should be 1459 
recorded.   Nutraceuticals and preventative treatment also should be recorded.  Medications only 1460 
taken as needed either can be recorded when prescribed or only recorded if used during the 1461 
study.  Glucagon for treatment of severe hypoglycemia will only be recorded if used during the 1462 
study. 1463 
 Prohibited Medications, Devices, Treatments, and Procedures  1464 
Participants using glulisine at the time of enrollment will be asked to contact their person al 1465 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the trial  1466 
in the case they are randomized to experimental arm . 1467 
Treatment with any non -insulin glucose -lowering agent (including GLP -1 agonists, Symlin, DPP - 1468 
4 inhibitors, SGLT -2 inhibitors, biguanides, sulfonylureas and naturaceuticals) will not be 1469 
permitted.  1470 
The investigational study devices (t:slim X2 insulin pump, study CGM systems) must be removed 1471 
before Magnetic Resonance Imaging (MRI), Computed Tomography ( CT) or diathermy treatment. 1472 
Participants may continue in the trial after temporarily discontinuing use if requiring one of the 1473 
treatments above.   1474 
 Precautionary Medications, Treatments, and Procedures  1475 
Not applicable.  1476 
 Prophylactic Medications, Treatments, and Procedures  1477 
Not applicable.  1478 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 63 OF 84 
 
 Rescue Medications, Treatments, and Procedures  1479 
All participants will be required to have a commercially available glucagon (or glucagon analog) 1480 
preparation for treatment as needed of severe hypoglycemia. 1481 
 Participant Compensation 1482 
Participant compensation will be specified in the informed consent form. 1483 
 Participant Withdrawal 1484 
Participation in the study is voluntary, and a participant may withdraw at any time.  For  participants 1485 
who withdraw, their data will be used up until the time of withdrawal.  1486 
 Confidentiality  1487 
For security and confidentiality purposes, participants will be assigned an identifier that will be 1488 
used instead of their name.  Protected health information gathered for this study will be shared 1489 
with the coordinating c enter, the Jaeb Center for Health Research in Tampa, FL.  De- identified 1490 
participant information may also be provided to research sites involved in the study. 1491 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 64 OF 84 
 Chapter 12:  Statistical Consideration 1492 
 Statistical and Analytical Plans 1493 
The approach to sample size and statistical analyses are summarized below. A detailed statistical 1494 
analysis plan will be written and finalized prior to the completion of the study. 1495 
 Statistical Hypotheses  1496 
The primary outcome for this study is CGM- measured % in range 70 -180 mg/dL over a 13- week 1497 
period. The intervention will be considered effective if the Closed-Loop Control [CLC] is 1498 
superior to Standard Care [ SC] using a statistical significance of α=0.05 and the model specified 1499 
below in Section 6 (i.e., p < 0.05). 1500 
The null/a lternative hypotheses are:  1501 
a. Null Hypothesis : There is no difference in mean CGM -measured % in range 70 -180 1502 
mg/dL over 13 weeks between SC  and CLC  1503 
b. Alternative Hypothesis : The mean CGM -measured % in range 70-180 mg/dL over 13 1504 
weeks is different for SC  and CL C. 1505 
 Sample Size 1506 
Based on data from the DCLP5 study mentioned above, we conservatively estimate the standard 1507 
deviation (SD) for the primary outcome, time in range (TIR), to be 10%. A sample size of N=90 1508 
subjects (60 in the CLC arm and 30 in the SC  arm) there fore will give 90% power to detect a 7.5% 1509 
improvement in TIR with a two -sided test and type 1 error of 5%. Accounting for potential attrition 1510 
rate of up to 10%, the total sample size for the PEDAP Study is estimated at N=102. 1511 
 1512 
The following table shows the  minimum detectable difference with a total sample size N=90 for 1513 
key secondary outcomes. The observed standard deviations are taken from the DCLP5 study. 1514 
 Standard Deviation  Correlation  
with  
Baseline  Effective  
SD a Detectable  
Difference 
with N=90 b Outcome CLC  
(n=78)  SC 
(N=22)  Pooled  
(N=100)  
% >250 mg/dL c 5.5% 9.9% 6.5% 0.69 4.7% 3.4% 
Mean Glucose d 18 26 20 0.68 14 10 
HbA1c  0.8% 0.9% 0.8% 0.70 0.6% 0.4% 
% <70 mg/dL c 1.07% 1.13% 1.08% 0.61 0.86% 0.63% 
% <54 mg/dL c 0.23% 0.23% 0.23% 0.54 0.19% 0.14% 
a – After accounting for the baseline value as a covariate in the regression model.  1515 
b – With 90% power and two- sided type 1 error rate = 5%.  1516 
c – Outcomes with a skewed distribution winsorized at the 10th and 90th percentiles.  1517 
d – Units for mean glucose are mg/dL.  1518 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 65 OF 84 
 
 Efficacy Outcome Measures  1519 
 
 1520 
• CGM -measured % in range 70 -180 mg/dL 1521 
 
 1522 
12.4.2.1 Secondary Efficacy Endpoints Included in Hierarchical Analysis  1523 
The following secondary endpoints will be tested in a hierarchical fashion as described in 1524 
section  12.7.1. 1525 
• CGM -measured % above 250 mg/dL 1526 
• CGM -measured mean glucose  1527 
• HbA1c at 13 weeks 1528 
• CGM -measured % below 70 mg/dL  1529 
• CGM -measured % below 54 mg/dL 1530 
12.4.2.2 Other Secondary Efficacy Endpoints  1531 
The following endpoints are considered exploratory. Type 1 error for these endpoints will be 1532 
controlled using the false discovery rate (FDR) instead of the familywise error rate (FWER).   1533 
CGM -Measured:  1534 
• % above 180 mg/dL 1535 
• % in range 70-140 mg/dL  1536 
• glucose variability measured with the coefficient of variation (CV) 1537 
• glucose variability measured with the standard deviation (SD) 1538 
• % <60 mg/dL 1539 
• low blood glucose index (LBGI)* 1540 
• hypoglycemic events ( defined as at least 15 consecutive minutes <54 mg/dL) 1541 
• hyperglycemic events ( defined as at least 90 consecutive min utes >300 mg/dL) 1542 
• % >300 mg/dL  1543 
• high blood glucose index (HBGI)* 1544 
• % in range 70- 180 mg/dL improvement from baseline to 13 weeks ≥5%  1545 
• % in range 70- 180 mg/dL improvement from baseline to 13 weeks ≥10%  1546 
• % time in range 70-180 mg/dL >70% and % time <70 mg/dL <4%  1547 
HbA1c: 1548 
• HbA1c <7.0% at 13 weeks 1549 
• HbA1c <7.5% at 13 weeks 1550 
• HbA1c improvement from baseline to 13 weeks >0.5% 1551 
• HbA1c improvement from baseline to 13 weeks >1.0% 1552 
• HbA1c relative improvement from baseline to 13 weeks >10% 1553 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 66 OF 84 
 • HbA1c absolute improvement from baseline to 13 weeks >1.0% or HbA1c <7.0% at 13 1554 
weeks  1555 
Questionnaires 1556 
• PedsQL Diabetes Module – total score and 5 subscales:  1557 
o Diabetes  1558 
o Treatment I  1559 
o Treatment II  1560 
o Worry  1561 
o Communication  1562 
• Pediatric Inventory for Parents (PIP) 2 domains each with a total score and 4 subscales for 1563 
(5x2=10 difference scores)  1564 
o Frequency  1565 
 Total Score  1566 
 Communication  1567 
 Medical Care  1568 
 Role Function 1569 
 Emotional Functioning 1570 
o Difficulty  1571 
 Same total + 4 subscales as above for Frequency  1572 
• INSPIRE (CLC arm only) 1573 
• Pittsburgh Sleep Quality Index (PSQI) global score 1574 
• Fear of Hypoglycemia Survey for Parents (HFS- P) – total score, 2 subscales and 4 factor 1575 
scores:  1576 
o Behavior  1577 
 Avoidance 1578 
 Maintain high BG 1579 
o Worry  1580 
 Helplessness  1581 
 Social consequences  1582 
 1583 
*Note that LBGI and HBGI will be calculated using all available CGM readings as described 1584 
below. Therefore, they may not be comparable to the same metrics calculated with SMBG data.  1585 
Other:  1586 
• Insulin 1587 
♦ Total daily insulin (units/kg) 1588 
♦ Percentage of total insulin delivered via basal  1589 
•  Weight and Body Mass Index (BMI) 1590 
 
 1591 
Randomization is preceded by 2-6 weeks of CGM run-in, which will be used in the calculation 1592 
of baseline CGM metrics. F or participants  who are eligible to skip the run-in, comparable 1593 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 67 OF 84 
 amount of CGM data from their own sensors will be taken before randomization visit to 1594 
calculate baseline CGM metrics . 1595 
CGM data starting from randomization visit through the 13- week visit will be included in the 1596 
calculation of each CGM metric. Percentages in range 70 -180 mg/dL (and all other CGM- based 1597 
metrics) will be calculated giving equal weight to each CGM point for each participant. 1598 
 Analysis Datasets and Sensitivity Analyses 1599 
All analyses comparing the CLC arm with SC  arm will follow intention -to-treatment approach, 1600 
which means participants will be analyzed in the treatment arm assigned by randomization 1601 
regardless of actual system use. All randomized participants will be included in the primary 1602 
analysis and secondary hierarchical analyses of CGM metrics. For other secondary outcomes, 1603 
only participants with non-missing outcome data will be included. 1604 
Safety outcomes will be reported for all enrolled participants, irrespective of whether the 1605 
participant was randomized or the study was completed. 1606 
 
 1607 
Per-protocol analyses will be performed for primary outcome and secondary hierarchical  1608 
outcomes only if >5% of participants will be excluded: 1609 
• CLC arm: Closed loop mode active for at least 80% of the time  1610 
• SC arm: CGM use for at least 80% of the time  1611 
 
 1612 
Confounding 1613 
A sensit ivity analysis will also be conducted if potential confounding factors collected at 1614 
baseline are detected.  1615 
The imbalance will be assessed based on clinical judgement reviewing the distributions in the 1616 
two treatment arms, not on a p-value. The person making this judgement will be unaware of 1617 
whether there is an association between baseline variables and study outcome. All variables 1618 
obtained on a continuous scale will be entered into the models as continuous variables, unless it 1619 
is determined that a variable does not have a linear relationship with the outcome. In such a case, 1620 
categorization and/or transformation will be explored. 1621 
Exclude First 2 Weeks of CGM Data  1622 
The primary analysis will be repeated by excluding the first 2 weeks of post-randomization CGM 1623 
data.  1624 
Missing Data 1625 
Missing data will be handled using direct likelihood method for the primary analysis. It is worth 1626 
noting that all statistical methods for handling missing data rely on untestable assumptions and 1627 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 68 OF 84 
 there is no one correct way to handle missing data. Our goal is to minimize the amount of 1628 
missing data so that the results will not be sensitive to which statistical method is used.  1629 
To that end, sensitivity analyses will be performed to explore whether results are similar for 1630 
primary analysis when using different methods. The following methods will be applied: 1631 
• Rubin’s multiple imputation with treatment group in the imputation model  1632 
• Available cases only  1633 
• Multiple imputation with pattern mixture model assuming the dropout trajectory of the 1634 
CLC group was that of the SC  group (Mallinckrodt and Clark, 2003) (3)  1635 
 Analysis of the Primary Efficacy Endpoint 1636 
Summary statistics (mean ± SD or median (quartiles)) will be reported by treatment group for the 1637 
CGM -measured % in range 70 -180 mg/dL at baseline, 13 weeks intervention and change from 1638 
baseline to 13 weeks. 1639 
CGM -measured % in range 70 -180 mg/dL between two treatment arms will be compared using a 1640 
linear mixed effects regression model while adjusting for baseline CGM- measured % in range 1641 
70-180 mg/dL, age, prior CGM and pump use, and clinical center (random effect). A point 1642 
estimate, 95% confidence interval and two- sided p- value will be reported for the treatment effect 1643 
based on the linear regression model and a 5% level will be used to declare statistical 1644 
significance. Residual values will be examined for an approximate normal distribution. If values 1645 
are highly skewed then robust regression using M-estimation will be used instead. However, 1646 
previous experience suggests that the residual values for % time glucose in target range wi ll 1647 
follow an approximately normal distribution. Imbalances between groups in important covariates 1648 
are not expected to be of sufficient magnitude to produce confounding. However, the presence of 1649 
confounding will be evaluated in the sensitivity analyses by including factors potentially 1650 
associated with the outcome for which there is an imbalance between groups ( 12.5.2).  1651 
In the primary analysis, any missing data at baseline or follow-up will be handled using direct 1652 
likelihood. A longitudinal linear regression model will be fit with the percent of time in range at 1653 
baseline and follow-up as the dependent variable. This model will adjust for age, prior CGM use 1654 
and pump use as fixed effects and clinical center as a random effect . This model adjusts for 1655 
baseline time in range by forcing the treatment groups to have the same mean value at baseline. 1656 
 Analysis of the Secondary Endpo ints 1657 
Point estimate s and confidence intervals for the treatment arm differences will be presented for 1658 
all secondary metrics. The models will adjust for the corresponding baseline metric, age, prior 1659 
CGM and pump use, and clinical center (random effect). 1660 
 
 1661 
To preserve the overall type 1 error for selected key secondary endpoints, a hierarchical testing 1662 
procedure will be used. If the primary analysis for time in range described above results in a 1663 
statistically significant result (p < 0.05),  then testing (similar to the model described above 1664 
for the primary outcome) will proceed to the next outcome metric in the following order: 1665 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 69 OF 84 
 • CGM -measured % in range 70 -180 mg/dL (primary outcome) 1666 
• CGM -measured % above 250 mg/dL 1667 
• CGM -measured mean glucose  1668 
• HbA1c at 13 weeks  1669 
• CGM -measured % below 70 mg/dL 1670 
• CGM -measured % below 54 mg/dL 1671 
 1672 
This process continues iteratively moving to the next variable down on the list until a non- 1673 
significant result (p ≥ 0.05) is observed, or all six  variables have been tested. If a non- significant 1674 
result is encountered, then formal statistical hypothesis tes ting is terminated and any variables 1675 
below on the list are not formally tested . 1676 
Regardless of the results of the hierarchical testing, summary statistics appropriate to the 1677 
distribution will be tabulated by treatment arm for each hierarchical outcome.  A 9 5% confidence 1678 
interval for the treatment arm difference will also be calculated for all five  secondary hierarchical 1679 
outcomes listed above.  However, a confidence interval that excludes zero will not be considered 1680 
a statistically significant result if an outcome variable higher on the hierarchical list failed to 1681 
reach statistical significance.  1682 
Analysis for each of the CGM metrics listed above for the hierarchical analysis will parallel the 1683 
analysis described for the primary outcome in Section 12.6. 1684 
HbA1c at 13 weeks will be compared between the two treatment arms using a linear model while 1685 
adjusting for baseline HbA1c, age, prior CGM and pump use, and clinical center (random 1686 
factor). Missing data will be handled using direct likelihood in a regression model including all 1687 
available central laboratory HbA1c measurements at baseline and 13 -week visits.  1688 
For all above analyses, regression diagnostics will be employed analogous to as described in 1689 
Section 12.6 for the primary outcome. 1690 
 
 1691 
For all other secondary endpoints, only participants with non- missing data will be included in 1692 
analyses (available cases method). Summary statistics (mean ± SD, median (IQR) or n (%)) 1693 
appropriate to the distribution will be tabulated for them at baseline, 13 weeks and for the 1694 
changes from baseline to 13 weeks. For continuous outcomes, linear regression models will be 1695 
used to compare the treatment effects while adjusting for corresponding baseline values (e.g., 1696 
baseline % in range 70 -140 mg/dL for comparing change in % in range 70-140 mg/dL from pre- 1697 
randomization CGM wear to 13 weeks post-randomization period), age, prior CGM and pump 1698 
use, and clinical center as a random effect. Comparisons of body weight and BMI will also be 1699 
adjusted for gender. 1700 
For CGM -measured hypoglycemia/hyperglycemia events, event rates per week will be compared 1701 
using similar linear mixed effects regression models as described above for the primary outcome. 1702 
 1703 
Binary HbA1c and CGM  Outcomes  1704 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 70 OF 84 
 For the binary HbA1c outcomes, risk-adjusted percentages by treatment group will be computed 1705 
at 13 weeks from a logistic regression model. The logistic regression will adjust for baseline 1706 
HbA1c (as a continuous factor), age, prior CGM and pump use as fixed effects, and clinical site 1707 
as a random effect. Similar analyses will be done for the binary CGM outcomes. 1708 
Questionnaires  1709 
For each questionnaire, mean ± SD or percentiles appropriate to the distribution will be given by 1710 
treatment group at baseline and 13 weeks. Group comparisons will be conducted for the total 1711 
score (mean score) and subscales from participant version and parent version separately using 1712 
similar linear models as described above. The INSPIRE and SUS post- treatment survey s will 1713 
only be administered to the CLC group at the 13-week visit, and thus the scores will only be 1714 
tabulated.  1715 
Focus Groups  1716 
Qualitative data from focus groups will be analyzed using NVIVO (release 11.2; QSR 1717 
International) to organize and manage the entire corpus of focus group data. Analysis begins 1718 
with an initial coding procedure to capture and describe the range of responses to the 1719 
intervention. A second, more focused and detailed level of coding will be applied to major 1720 
categories of findings in the initial review to determine themes in response to the clinical trial, 1721 
use of the closed loop system, and quality of life changes. The video data from the co-regulation 1722 
interaction will be submitted to the validated coding system and frequencies of positive and 1723 
negative interactions , treatment discussions, and CLC comments will be calculated with simple 1724 
descriptive statistics. Change from pre to post treatment will be analyzed in the similar GLM 1725 
framework to evaluate whether there is improvement in co -regulation across the study. 1726 
Boxplots 1727 
Boxplots stratified by treatment group will be given for the primary outcome and each of the key 1728 
secondary endpoints in specified  time  periods over the 13-week course of follow-up. 1729 
 Safety Analyses 1730 
All randomized participants will be included in these analyses and all their post -randomization 1731 
safety events will be reported.  Any pre- randomization adverse events will be tabulated separately 1732 
and will include any participants who were never randomized. 1733 
Safety analyses of the main study (randomized tri al phase) will include events  occurring on or 1734 
after randomization until and including the 13-week visit or Day 105 from randomization, 1735 
whichever occurs first. Safety analyses of the extension phase will include subsequent events 1736 
until the last visit date o r the last event date (whichever is later).  1737 
For the following outcomes, the number of events will be tabulated by treatment group. F ormal 1738 
statistical comparisons (main study phase only) will be performed if there are enough events (at 1739 
least 5 events combin ed between the two treatment groups): 1740 
• Number of SH events and SH event rate per 100 person- years  1741 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 71 OF 84 
 • Number of DKA events and DKA event rate per 100 person- years  1742 
• Other serious adverse events  1743 
• Any adverse event rate  1744 
• Number of calendar days with any ketone level ≥ 1.0 mmol/L (if ≥5 total calendar days 1745 
combined) 1746 
• Worsening of HbA1c from baseline to 13 weeks by >0.5% 1747 
• Investigational device related (intervention group only): 1748 
o Adverse device effects (ADE)  1749 
o Serious adverse device events (SADE)  1750 
o Unanticipated adverse device effects (UADE)  1751 
 1752 
For DKA and SH events, if enough events, the rates will be compared between the two treatment 1753 
arms during the main study phase using a robust Poisson regression. The regression will adjust 1754 
for the participant -reported number of SH events 12 months prior to the start of the study and 1755 
clinical center as random effect. The amount of follow up will be included as an offset covariate 1756 
to compare the rates. A similar analysis will be done for DKA, if at least 5 total DKA events 1757 
among both treatment groups.  1758 
 1759 
 Intervention Adherence  1760 
The following tabulations and analyses will be performed by treatment group to assess 1761 
intervention adherence for the study: 1762 
• Sensor use –percent time of use, overall for 13-week visit 1763 
For CLC arm only, the following will be tabulated to assess adherence: 1764 
• Closed loop system use–percent time of use, overall for 13-week visit 1765 
• % time in different operational modes - overall and by specified time periods  1766 
 Protocol Adherence and Retention  1767 
The following tabulations and analyses will be performed by treatment group to assess protocol 1768 
adherence for the study: 1769 
• Number of protocol and procedural deviations  1770 
• Flow chart accounting for all enrolled participants up to randomization 1771 
• Flow chart of all randomized participants at  all scheduled visits and phone contacts post 1772 
treatment initiation  1773 
• Number of and reasons for unscheduled visits and phone calls 1774 
• Number of participants who stopped treatment and reasons 1775 
 Baseline Descriptive Statistics  1776 
Baseline demographic and clinical characteristics of the cohort of all randomized participants 1777 
will be summarized in a table using summary statistics appropriate to the distribution of each 1778 
variable. Descriptive statistics will be displayed by treatment group for the following: 1779 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 72 OF 84 
 • Age 1780 
• Sex 1781 
• Race/Eth nicity  1782 
• Parent’s income, education, and/or insurance status 1783 
• Diabetes duration  1784 
• Insulin method before enrollment (pump vs. MDI) 1785 
• CGM use before enrollment 1786 
• HbA1c  1787 
• BMI  % 1788 
• Participant -reported number of SH and DKA 12 months prior to the start of the study 1789 
• Baseline CGM metrics including: 1790 
• % in range 70-180 mg/dL 1791 
• % time > 180 mg/dL 1792 
• Mean glucose 1793 
• % time < 70 mg/dL  1794 
• % time < 54 mg/dL  1795 
 Device Issues  1796 
The following tabulations and analyses will be performed by treatment group to assess device 1797 
issues:  1798 
• Device malfunctions requiring study team contact and other reported device issues 1799 
• Rate of different failure events and alarms per 24 hours recorded by the Control- IQ system – 1800 
overall and by month 1801 
 Planned Interim Analyses  1802 
No formal interim efficacy analyses are pl anned. The analysis of the RCT will be performed on 1803 
completion of the RCT prior to the completion of the extension phase. 1804 
In addition, the DSMB will review safety data at intervals, with no formal stopping rules.  1805 
 Subgroup Analyses  1806 
In exploratory analyses, the primary outcome (time 70 -180 mg/dL), % time <70 mg/dL and HbA1c 1807 
at 13 weeks will be assessed separately in various subgroups. Subgroups will be defined according 1808 
to the baseline value of the factors, which will be noted in the SAP . Tests for interaction 1809 
with treatment group will be performed. 1810 
Interpretation of subgroup analyses will be viewed with caution, particularly in the absence of an 1811 
overall significant difference. For continuous variables, results will be displayed in subgroups 1812 
based on cutpoints although the analysis will utilize the variable as continuous. If there is 1813 
insufficient sample size in a given subgroup, the cutpoints for continuous measures may be 1814 
adjusted per the observed distribution of values. Cutpoint selection for display purpose s will be 1815 
made masked to the outcome data. 1816 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 73 OF 84 
 
 Multiple Comparison/Multiplicity  1817 
Primary Analysis 1818 
Since there will be a single comparison for the primary outcome (CGM -measured % 70 -180 1819 
mg/dL), no adjustment is needed. 1820 
Secondary Hierarchical Analyses 1821 
The hierarchical testing procedure described above in section 12.7.1 will be used to control the 1822 
overall type 1 error for the primary outcome plus five key secondary outcomes identified above. 1823 
All Other Secondary Analyses 1824 
For comparison of all other efficacy endpoints, the false discovery rate will be controlled using the 1825 
adaptive Benjamini -Hochberg procedure (4). 1826 
P-values from safety analyses, sensitivity analyses, and per-protocol analyses will not be adjusted 1827 
for multiple comparisons. 1828 
 Exploratory Analyses 1829 
CGM Metrics  1830 
In addition to the analysis for the CGM -measured  endpoints described earlier, separate analyses 1831 
will be conducted for daytime and nighttime of the following metrics: 1832 
• % time in range 70- 180 mg/dL  1833 
• Mean glucose 1834 
• % above 180 mg/dL 1835 
• % below 70 mg/dL 1836 
• coefficient of variation  1837 
 1838 
Above selected CGM metrics also wil l be reported by restricting the CGM data in the CLC arm 1839 
based on following criteria. No p -values will be calculated for following analyses.  1840 
• using only the CGM data when the closed-loop is active 1841 
 1842 
Additional Insulin Metrics 1843 
The following insulin metrics will be tabulated by treatment groups at baseline, 13 weeks and for 1844 
the changes from baseline to 13 weeks. No p- values will be calculated for these metrics.  1845 
• Total daily basal insulin (units/kg) 1846 
• Total daily bolus insulin (units/kg) 1847 
• Total daily manual bolus (units/kg) 1848 
• Total daily automated bolus (units/kg) 1849 
• Total daily short-acting injections for injection users 1850 
 1851 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 74 OF 84 
 The following will be calculated for the CLC group in the 1-week prior to randomization and by 1852 
1-week follow-up periods from pump data only: 1853 
• Total daily insulin (units/kg) 1854 
• Total daily basal insulin (units/kg) 1855 
• Total daily bolus insulin (units/kg) 1856 
o Total daily manual bolus (units/kg) 1857 
o Total daily automated bolus (units/kg) 1858 
• Number of manual insulin doses per day 1859 
• Number of manual insulin doses with carb announcement per day 1860 
 1861 
 Extension Phase 1862 
Analyses for the extension phase will be primarily exploratory.  1863 
 1864 
For both treatment arms , summary statistics will be given for all outcomes listed above  in 1865 
Section 12.4 at RCT baseline (pre-randomization), 13 weeks, and 26 weeks. In addition, boxplots 1866 
will be constructed for each of the outcome metrics listed above showing both treatment arms 1867 
over the course of the combined RCT and extension (where both arms using CLC) phases. 1868 
Formal statistical comparisons between the two study phases (i.e., primary RCT and extension 1869 
phases) will be performed for key outcome measures including: 1870 
• CGM -measured % in range 70 -180 mg/dL 1871 
• CGM -measured % ab ove 250 mg/dL 1872 
• CGM -measured mean glucose  1873 
• HbA1c at 13 weeks 1874 
• CGM -measured % below 70 mg/dL 1875 
• CGM -measured % below 54 mg/dL 1876 
• PedsQL Diabetes Module – total score  1877 
• Pediatric Inventory for Parents (PIP) 1878 
 Frequency domain total score 1879 
 Difficulty domain total score  1880 
• INSPIRE Survey  1881 
• Pittsburgh Sleep Quality Index (PSQI) global score 1882 
• Fear of Hypoglycemia Survey for Parents (HFS- P) – total score  1883 
• Hypoglycemia Confidence Scale (HCS)  1884 
• System Usability Scale (SUS)  1885 
For each of these outcomes a longitudinal regression model will be fit combining data from the 1886 
RCT and extension phases a ccounting for the correlated data from repeated measures. Treatment 1887 
group will be a time dependent factor in this model. A point estimate and 95% confidence 1888 
interval will be given for the estima ted effects of each CLC version used during the study, both 1889 
with respect to SC and with respect to one another. Safety analyses of the Extension Phase will 1890 
include events occurring on or after the Extension training visit until the end of the 26- Week visit 1891 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 75 OF 84 
 or the end of Day 105 from the Extension training visit — whichever occurs first. Safety 1892 
outcomes will include those specified in section 12.8 with the exception of worsening of HbA1c. 1893 
Summary statistics appropriate to the distribution will be tabulated without any formal 1894 
comp arisons by treatment group for the safety outcomes noted in section 12.8. 1895 
 
 1896 
According to Chapter 14, during the extension phase, 30 – 40 participants will be sought to 1897 
enroll in an ancillary study to test the Control- IQ system with meal bolus and exercise 1898 
challenges. The analyses for this ancillary study are specified in Section 14.5. Data collected 1899 
from the start of each of these challenges until 5:59 AM the following morning will be excluded 1900 
from th e analysis of the extension phase. 1901 
 1902 
 Extended Use Period  1903 
Analyses for the extended use phase will be exploratory.  1904 
 1905 
Summary statistics will be given for all outcomes listed above in Section 12.4 for each of the 13- 1906 
week periods following initiation of the Extended Use period. In addition, boxplots will be 1907 
constructed for each of the outcome metrics listed above for these periods. 1908 
 1909 Safety analyses of the Extended Use period will include events unti l the last visit date or the last 1910 
event date (whichever is later).  Safety outcomes will include those specified in section 12.8 with 1911 
the exception of worsening of HbA 1c. 1912 
  1913 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 76 OF 84 
 Chapter 13:  Data Collection and Monitoring  1914 
 Case Report Forms and Device Data  1915 
The main study data are collected on electronic case report forms (CRFs). When data are directly 1916 
collected in electronic case report forms, this will be considered the source data. For any data 1917 
points for which the eCRF is not considered source (e.g. lab results that are transcribed from a 1918 
printed report into the eCRF), the original source documentation must be maintained in the 1919 
participant’s study chart or medical record. This source must be readily verifiable against the 1920 
values entered into eCRF. Even where all study data are directly entered into the eCRFs at office 1921 
visits, evidence of interaction with a live subject must be recorded (e.g., office note, visit record, 1922 
etc.).    1923 
Electronic device data files are obtained from the study software and individual hardware 1924 
components.  These electronic device files are considered the primary source documentation. 1925 
 Study Records Retention  1926 
Each participating site will maintain appropriate medical and research records for this trial, in 1927 
compliance with ICH E6 and regulatory and institutional requirements for the protection of 1928 
confidentiality of participants.  1929 
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 1930 
application in an ICH region and until there are no pending or contemplated marketing applications 1931 
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical 1932 
development of the investigational product.  These documents should be retained for a longer 1933 
period, however, if required by local regulations.  No records will be destroyed without the written 1934 
consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 1935 
investigator when these documents no longer need to be retained. 1936 
 Quality Assurance and Monitoring  1937 
Designated personnel from the Coordinating Center will be responsible for maintaining quality 1938 
assurance (QA) and quality control (QC) systems to ensure that the clinic al portion of the trial is 1939 
conducted and data are generated, documented and reported in compliance with the protocol, 1940 
Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as to ensure 1941 
that the rights and wellbeing of trial participants are protected and that the reported trial data are 1942 
accurate, complete, and verifiable.  Adverse events will be prioritized for monitoring. 1943 
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 1944 
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 1945 
Investigations — A Risk -Based Approach to Monitoring” (August 2013).  Study conduct and 1946 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan describes in 1947 
detail who will conduct the monitoring, at what frequency monitoring will be done, at what level 1948 
of detail monitoring will be performed, and the distribution of monitoring reports. 1949 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 77 OF 84 
 The data of most importance for monitoring at the site are participant eligibility  and adverse 1950 
events.  Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1951 
monitoring will be performed in real- time with on -site monitoring performed to evaluate the 1952 
verity and completeness of the key site data.  Elements of the RBM may include: 1953 
• Qualification assessment, training, and certification for sites and site personnel 1954 
• Oversight of Institutional Review Board (IRB) coverage and informed consent procedures 1955 
• Central (remote) data monitoring: validation of data entry, data edi ts/audit trail, protocol 1956 
review of entered data and edits, statistical monitoring, study closeout 1957 
• On-site monitoring (site visits): source data verification, site visit report 1958 
• Agent/Device accountability  1959 
• Communications with site staff  1960 
• Patient retention and  visit completion  1961 
• Quality control reports 1962 
• Management of noncompliance 1963 
• Documenting monitoring activities  1964 
• Adverse event reporting and monitoring 1965 
Coordinating Center representatives or their designees may visit the study facilities at any time in 1966 
order to maintain current and personal knowledge of the study through review of the records, 1967 
comparison with source documents, observation and discussion of the conduct and progress of the 1968 
study. The investigational site will provide direct access to all trial related  sites, source 1969 
data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and 1970 
inspection by local and regulatory authorities. 1971 
 Protocol Deviations 1972 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1973 
requirements.  The noncompliance may be either on the part of the participant, the investigator, 1974 
or the study site staff.  As a result of deviations, corrective actions are to be developed by the site 1975 
and implemented promptly. 1976 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  Further 1977 
details about the handling of protocol deviations will be included in the monitoring plan. 1978 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 78 OF 84 
 Chapter 14:  Ethics/Protection of Human Participants  1979 
 Ethical Stan dard  1980 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1981 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1982 
CFR Part 56, and/or the ICH E6. 1983 
 Institutional Review Boar ds 1984 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1985 
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 1986 
form must be obtained before any participant is enrolled.  Any amendment to the protocol will 1987 
require review and approval by the IRB before the changes are implemented to the study.  All 1988 
changes to the consent form will be IRB approved; a determination will be made regarding whether 1989 
previously consented participants need to be re- consented.  1990 
 Informed Consent Process  1991 
 
 1992 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 1993 
the study and continues throughout the individual’s study participation.  Extensive discussion of 1994 
risks and possible benefits of participation will be provided to the participants and their families.  1995 
Consent forms will be IRB-approved and the participant will be asked to read and review the 1996 
document.  The investigator will explain the research study to the participant and answer any 1997 
questions that may arise.  All participants will receive a verbal explanation in terms suited to 1998 
their comprehension of the purposes, procedures, and potential risks of the study and of thei r 1999 
rights as research participants.  Participants will have the opportunity to carefully review the 2000 
written consent form and ask questions prior to signing. 2001 
The participants should have the opportunity to discuss the study with their surrogates or think 2002 
about it prior to agreeing to participate.  The participant will sign the informed consent document 2003 
prior to any procedures being done specifically for the study. The participants may withdraw 2004 
consent at any time throughout the course of the trial.  A copy of  the informed consent document 2005 
will be given to the participants for their records.  The rights and welfare of the participants will 2006 
be protected by emphasizing to them that the quality of their medical care will not be adversely 2007 
affected if they decline t o participate in this study . 2008 
 
 2009 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, 2010 
and the sponsor(s) and their agents.  This confidentiality is extended to cover testing of 2011 
biological samples and genetic tests in addition to the clinical information relating to 2012 
participants.  Therefore, the study protocol, documentation, data, and all other information 2013 
generated will be held in strict confidence.  No information concerning the study or the data will 2014 
be released to any unauthorized third party without prior written approval of the sponsor. 2015 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 79 OF 84 
 The study monitor, other authorized representatives of the sponsor, representatives of the IRB, 2016 
regulatory agencies or  company supplying study product may inspect all documents and records 2017 
required to be maintained by the investigator, including but not limited to, medical records 2018 
(office, clinic, or hospital) and pharmacy records for the participants in this study.  The clinical 2019 
study si te will permit access to such records.  2020 
The study participant’s contact information will be securely stored at each clinical site for 2021 
internal use during the study.  At the end of the study, all records will continue to be kept in a 2022 
secure location for as l ong a period as dictated by the reviewing IRB, institutional policies, or 2023 
sponsor requirements. 2024 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, 2025 
will be transmitted to and stored at the Jaeb Center for Health Research (JCHR) .  This will not 2026 
include the participant’s contact or identifying information, unless otherwise specified in the 2027 
informed consent form.  Rather, individual participants and their research data will be identified 2028 
by a unique study identification number.  The study data entry and study management systems 2029 
used by clinical sites and by JCHR  research staff will be secured and password protected.  At the 2030 
end of the study, all study databases will be de -identified and archived at the JCHR  and the 2031 
University of Virginia Center for Diabetes Technology. 2032 
  2033 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 80 OF 84 
 Chapter 15:  Ancillary Study to Test Control -IQ System with Meal 2034 
Bolus and Exercise Challenges  2035 
 Obje ctive  2036 
This A ncillary Study will assess the safety of using the study system during exercise and meal 2037 
bolus- related challenges . Outcome data are expected to be used to support regulatory filings for 2038 
the device system .  2039 
 Sample Size 2040 
Participation in the Ancillary Study will be offered to participants who are currently in the 2041 
Extension Phase of the main study. The  goal for sample size is to have 30- 40 individuals 2042 
participate in the Ancillary Study . 2043 
 Eligibility Cr iteria  2044 
Participants must be currently in the Extension Phase of the main study, with at least 2 weeks 2045 
and no more than 11 weeks completed to ensure sufficient comfort with the study pump and 2046 
sufficient time to complete the protocol below .  2047 
Inclusion in the Ancillary Study requires investigator judgment that it is safe for the individual to 2048 
participate.  2049 
 Study Pro cedures  2050 
On the day of enroll ment into the Ancillary Study , informed consent will be obtained from 2051 
interested participants, and eligibility will be verified.  2052 
A paper logbook will be provided to participants that includes a page to record details about each 2053 
challenge and procedural instructions about how participants will conduct these challenges. This 2054 
material will be reviewed with each participant.  2055 
During home use, each participant  will perform 3 exercise  and meal  bolus- related  challenges 2056 
(details below) appropriate for the age of the participant. Each challenge will be separated from 2057 
the other challenges by at least 48  hours. Before starting each challenge, caregivers  of the child 2058 
must assure the child has a working CGM and Control- IQ is active.  If activity is paused  during 2059 
an exercise- related challenge, the challenge may be continued to allow for continuation of the 2060 
activity if  the participant  is able and willing to continue. 2061 
Participants  will receive a guidance document for performing the challenges that includes the 2062 
following safety mitigations: 2063 
• The participant’s parent or guardian must remain with the child at all times and 2064 
monitor CGM readings frequently during and for at least two hours after completion 2065 
of each  challenge. 2066 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 81 OF 84 
 • The hyperglycemia safety protocol described in section 8.2.4 will be followed during 2067 
each challenge. 2068 
• The parent/guardian must have an on-call phone number for the study team prior to 2069 
initiation of each challenge. 2070 
• CGM glucose must be ≥ 120 mg/dL prior to initiation of each exercise- related 2071 
challenge.  2072 
• Exercise may not be initiated during an exercise- related challenge if the CGM trend 2073 
arrows on the study insulin pump indicate Falling glucose (down arrow) or Rapidly 2074 
Falling glucose (double down arrow). 2075 
• Snacks and glucagon must be available for use during and after each exercise- related 2076 
challenge. 2077 
• Control- IQ exercise activity mode must be activated at least 30 minutes prior to the 2078 
start of exercise during each exercise -related  challenge and kept  active for at least 30 2079 
minutes after completion of the exercise period. 2080 
• Additional carbohydrate may be given as needed at the start  of, during, or after each 2081 
exercise- related challenge. 2082 
• The temp orary  basal rate feature of the study pump may be used if des ired to reduce 2083 
insulin delivery during the exercise period of each exercise- related challenge.  2084 
• Fingersticks will be performed for any low CGM value <70 mg/dL, and any exercise 2085 
should be stopped if BG is confirmed <70 mg/dL. Exercise may be stopped for 2086 
concerns for CGM decreasing at any time, even if CGM is >70 mg/dL. 2087 
• A parent/guardian will sleep in the same home as the child overnight and closely 2088 
monitor CGM readings following days when one of the challenges was performed. 2089 
Contact with the study investigat or may  be initiated at any time.  2090 
Challenge Details:  2091 
Missed Meal Bolus  Challenge : Participants  will skip their meal bolus for an afternoon meal of 2092 
at least 20 grams carbohydrate. The meal timing and carb amount and any additional snacks 2093 
given will be recorded on a study exercise log. Additional insulin boluses may be given for 2094 
hyperglycemia as needed.  The hyperglycemia safety protocol described in section 8.2.4 will be 2095 
followed. 2096 
Full Meal Bolus Plus Exercise Challenge : Participants  will receive a full meal bolus for an 2097 
afternoon meal of at least 20 grams carbohydrate. The pump’s Exercise Activity setting will be 2098 
turned on upon completion of the meal. Beginning 30 minutes after  completion of the meal, a 2099 
parent /guardian will try to keep the child physically active (walking, running, playing) for at 2100 
least 30  minutes if possible, or longer if desired. This can be mixed with mild activity. The meal 2101 
timing and carb amount, the actual stop  and start time of exercise, any associated hypoglycemia 2102 
treatments , and any additional snacks given will be recorded on a study exercise log. 2103 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 82 OF 84 
 Exercise Challenge: At least 2 hours after the child finishes an afternoon meal, a 2104 
parent/guardian will try to keep the child physically active (walking, running, playing) for at 2105 
least 30  minutes if possible, or longer if desired. This can be mixed with mild activity. The 2106 
pump’s Exercise Activity setting will be turned on 90 minutes after completion of the meal. The 2107 
meal timing and carb amount of the last meal prior to exercise, the actual start  and stop time of 2108 
exercise, any associated hypoglycemia treatments , and any additional snacks given will be 2109 
recorded on a study exercise log. 2110 
A challenge may be stopped for any reason, including participant non-cooperation, or concern 2111 
for hypoglycemia, or repeated hypoglycemia. 2112 
 Outcomes and Analysis Plan 2113 
A separate statistical analysis plan will be written for the Ancillary Study.  2114 
Outcomes will include the following: 2115 
Key Safety Outcomes:  2116 
• Severe hypoglycemia 2117 
• Other adverse ev ents 2118 
All adverse events will be listed. Listings will include Participant ID, the event, whether the 2119 
event was serious, whether the event was related to the study device, the event outcome, and a 2120 
description of the event. 2121 
 2122 
Other Outcomes  2123 
• CGM -measured %  <54 mg/dL  overnight (all challenge types)  2124 
• CGM -measured %  <70 mg/dL overnight (all challenge types)  2125 
• CGM -measured %  >180 mg/dL overnight (all challenge types)  2126 
• CGM -measured %  <54 mg/dL  during the two hours immediately following the start of 2127 
exercise for each exercise- related challenge  2128 
• CGM -measured % <70 mg/dL during the two hours immediately following the start of 2129 
exercise for each exercise- related challenge  2130 
• CGM -measured %  >180 mg/dL during the four hours following the announced meal, or 2131 
until the next meal bolus is given, for the missed meal bolus challenge 2132 
• CGM -measured %  >300 mg/dL during the four hours following the announced meal, or 2133 
until the next meal bolus is given, for the missed meal bolus challenge 2134 
The percentage of time spent below 54 mg/dL from 10 PM – 5:59 AM  the night of a n exercise 2135 
challenge will be compared with percentage of time spent below 54 mg/dL the previous night 2136 
using a linear mixed effects regressio n model. A point estimate, 95% confidence interval and 2137 
two-sided p-value will be reported for the challenge effect based on the linear regression model 2138 
and a 5% level will be used to declare statistical significance. Residual values will be examined 2139 
for an  approximate normal distribution. If values are highly skewed, then robust regression using 2140 
M-estimation will be used instead.  Analysis of the percentage of time spent below 70 mg/dL 10 2141 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 83 OF 84 
 PM – 5:59 AM  the night of a n exercise challenge will be performed in t he same manner.  2142 
 2143 
The percentage of time spent above 180 mg/dL from 10 PM – 5:59 AM  the night of a missed 2144 
meal bolus challenge will be compared with percentage of time spent above 180 mg/dL the 2145 
previous night using a linear mixed effects regression model. A point estimate, 95% confidence 2146 
interval and two-sided p-value will be reported for the challenge effect based on the linear 2147 
regression model and a 5% level will be used to declare statistical significance. Residual values 2148 
will be examined for an approximate normal distribution. If values are highly skewed, then 2149 
robust regression using M- estimation will be used instead.  Analysis of the percentage of time 2150 
spent above 300 mg/dL 10 PM – 5:59 AM  the night of a mis sed meal bolus challenge will be 2151 
performed in the same manner.  2152 
 2153 CGM -measured % <54 mg/dL during the two hours immediately following the start of exercise 2154 
for each exercise challenge will be compared between the two exercise challenge groups using a 2155 
paired t -test. CGM -measured % <70 mg/dL during this same period  will be analyzed in the same 2156 
manner.  2157 
 2158 For each  challenge type, the mean, standard deviation, and range will be given for the outcomes 2159 
listed above relevant to the challenge type. Summary statistics for the overnight periods 2160 
preceding the challenges will be presented with summary statistics for each challenge type.
 2161 
Safety Monitoring 2162 
Safety ov ersight will be the same as for the main study, as described in Chapter 10:.    2163 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 84 OF 84 
 Chapter 16:  References 2164 
1. Brown  S, Kovatchev B , Raghinaru D, Lum JW , Buckingham  BA, Kudva YC, Laffel  LM, 2165 
Levy CJ,  Pinsker JE , Wadwa RP , Dassau  E, Doyle FJ , Anderson SM, Church MM, Dadlani 2166 
V, Ekhlaspour L, Forlenza GP, Isga naitis E, Lam DW, Kollman C, and Beck RW , for the 2167 
iDCL Trial Research Group : Six-Month Randomized, Multicenter Trial of Closed-Loop 2168 
Control in Type 1 Diabetes. N Engl J Med. 2019 Oct 31;381(18):1707-1717. doi: 2169 
10.1056/NEJMoa1907863. 2170 
2. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, 2171 
Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CK, Dokken BB, Weinzimer 2172 
SA, DeBoer MD, Buckingham BA, Cher ñavvsky D, and Wadwa R P, for the iDCL Trial  2173 
Research Group:  A Randomized T rial of Closed -Loop Control in Children with Type 1 2174 
Diabetes . N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736. 2175 
3. Mallinckrodt CH, Clark WS, et al: Assessing responses profiles from incomplete longitudinal 2176 
clinical trial data under regula tory considerations, J. Biopharm. Stat., 2003; 13(2): 179-190. 2177 
4. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and 2178 
powerful approach to multiple testing. J. R. Statist. Soc. B, 57, 289–300. 2179 